

RESEARCH

Open Access



MMP-3 cleavage of Lamin A induces pro-migratory nuclear deformity, nucleophagy, and their autophagic secretion with extracellular vesicles in metastatic cancer

Takanori Eguchi^{1*}, Eman A. Taha², Keisuke Nakano³, Vikas Tiwari⁴, Katsuki Takebe¹, Tomohiro Inoue^{1,5}, Lizi Xing^{1,6}, Chiharu Sogawa⁷, Kuniaki Okamoto¹ and Stuart K. Calderwood⁸

Abstract

Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases that cleave a plethora of substrates, including components of the extracellular matrix and cell-surface-associated proteins, as well as intracellular targets. MMPs have also been found in extracellular vesicles (EVs), such as exosomes. MMP-3 promotes tumor growth, epithelial-to-mesenchymal transition, genome instability, migration, invasion, and metastasis of cancer cells, and nuclear MMP-3 controls gene transcription. Intranuclear proteolysis by MMPs may significantly alter cancer progression. However, the nuclear substrates of MMP-3 have not been well investigated. In this study, we performed proteomic analyses to identify the nuclear substrates and EV proteins regulated by MMP-3. While rapidly metastatic colon cancer (LuM1) three-dimensionally cultured tumoroids secreted EVs containing 30 protein types, including Lamin A (LMNA), MMP-3, fibronectin (FN1), HSPA8 (Hsc70), β -actin (ACTB), and vimentin (VIM), CRISPR/Cas9-based knockout of MMP-3 reduced the secretion of these proteins in EVs. Notably, EV-bound cleaved Lamin secretion was confirmed by immunoelectron microscopy. Also, MMP-3 formed proteolytic dimers via its hemopexin-like repeat domains in nuclei. Many nuclear MMP-3-binding proteins, including Lamin A/C, histones, topoisomerases, and hnRNPs, were screened by co-immunoprecipitation followed by proteomics. Proteolytic MMP-3 overexpression generated a C-terminal 30-kDa fragment of Lamin A, whose cleavage site was defined via structural analysis. MMP-3 digestion of Lamin A induced nuclear deformity (atypia) required for cell migration in confined space. The cleaved Lamin A and MMP-3 were transported with autophagosomes (LC3B+), nucleophagosomes, and amphisomes (CD63+LC3B+) and co-secreted with EVs. Proteolytic MMP-3 also induced nuclear speckles of Lamin A, suggesting their roles in transcription and splicing. Clinical analysis revealed that high expressions of *MMP3* and *LMNA* were significantly seen in head and neck squamous cell carcinoma (HNSC) than in the other 16 cancer types, and predicted poor prognosis of patients suffering from HNSC, pancreatic, rectum and lung adenocarcinomas at specific stages. Immunohistochemistry revealed that nuclear MMP-3 and cleaved Lamin were significantly higher expressed in stage IV metastatic HNSC cases than in stage I non-metastatic cases. Taken

*Correspondence:

Takanori Eguchi
eguchi@okayama-u.ac.jp

Full list of author information is available at the end of the article



© The Author(s) 2026. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

together, MMP3-cleavage of Lamin A induces nuclear deformity, nucleophagy, and their autophagic co-secretion with EVs in metastatic cancer. Also, high expression of MMP-3 and secretion of Lamin A can predict poor prognosis in multiple cancer types at specific stages.

Plain english summary

Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases that cleave a wide range of substrates, including components of the extracellular matrix and cell-surface-associated proteins, as well as intracellular targets. MMP-3 promotes tumor growth, migration, invasion, and metastasis of cancer cells, and nuclear MMP-3 controls gene transcription. Here, we performed proteomic analyses to identify the nuclear substrates and extracellular vesicle (EV)-bound proteins regulated by MMP-3. While three-dimensionally cultured, rapidly metastatic colon cancer tumoroids secreted EVs containing 30 protein types, including Lamin A (LMNA), MMP-3, and vimentin (VIM), knockout of MMP-3 reduced the secretion of these proteins in EVs. EV-bound cleaved Lamin secretion was confirmed by immunoelectron microscopy. Nuclear MMP-3 formed proteolytic dimers via its PEX domains. Many nuclear MMP-3-binding proteins, including LMNA, were screened by proteomics. MMP-3 overexpression generated a C-terminal 30-kDa fragment of LMNA, whose cleavage site was defined via structural analysis. MMP-3 digestion of Lamin A induced nuclear deformity required for cell migration in confined space. The cleaved LMNA and MMP-3 were co-transported via autophagosomes and amphisomes and co-secreted with EVs. MMP-3 also induced LMNA nuclear speckles. Clinically, high expressions of *MMP3* and *LMNA* were seen in head and neck squamous cell carcinoma (HNSC) than in the other 16 cancer types, and predicted poor prognosis in HNSC, pancreatic, rectum and lung adenocarcinomas at specific stages. Nuclear MMP-3 and cleaved Lamin were significantly higher expressed in metastatic HNSC cases than in non-metastatic cases. Taken together, MMP3-cleavage of Lamin A induces nuclear deformity and their autophagic co-secretion with EVs in metastatic cancer. Also, high expression of MMP-3 and secretion of Lamin A can predict poor prognosis in multiple cancer types at specific stages.

Keywords Lamin A (LMNA), Matrix metalloprotease (MMP), Proteolysis, Extracellular vesicle (EV), Exosome, Autophagy, Amphisome, Proteome, Nuclear deformity, Migration, Metastatic cancer, Head and neck squamous cell carcinoma, Colorectal cancer

Introduction

Cancer is a leading cause of death worldwide. There were close to 20 million new cases of cancer in the year 2022, alongside 9.7 million deaths from cancer [1]. Cancer metastasis is the primary reason most cancer patients die. While the primary tumor can be treated, metastasis often leads to organ damage and failure, ultimately causing death. For example, head and neck squamous cell carcinoma (HNSC) ranks as the seventh most common malignancy worldwide, with approximately 890,000 new cases and 450,000 deaths annually, accounting for 4.5% of global cancer diagnoses and fatalities [2]. Oral squamous cell carcinoma (OSCC) is the most prevalent form of head and neck cancer and represents approximately 90% of all cases [1]. OSCC alone contributes to 3% of global malignancies and is the 17th leading cause of cancer-related mortality [3, 4]. Despite recent advancements in many therapeutic strategies, HNSC remains associated with recurrence and progression. More than 50% of HNSC patients exhibit lymph node metastasis, one of the most common adverse prognostic factors in HNSC patients [4]. The 5-year survival rate of primary HNSC patients is greater than 80% but it falls to 40% with cervical lymph node metastasis and to 20% with distant metastases [5].

Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases that belong to the group of endopeptidases or matrixins [6]. They can cleave a plethora of substrates, including components of the extracellular matrix (ECM) and cell-surface-associated proteins, as well as intracellular targets. Accordingly, MMPs play key roles in a variety of physiological and pathological processes, such as tissue homeostasis and cancer cell invasion in the tumor microenvironment (TME) [7]. For example, MMPs, including MMP-2, MMP-9, and MT1-MMP (aka MMP-14), cleave laminins, thereby destroying the basement membrane and promoting epithelial-to-mesenchymal transition (EMT), migration, and invasion of epithelial cancer cells [8, 9]. Notably, MMP-3 promotes tumor growth, EMT, genome instability, migration, invasion, and metastasis of cancer cells [10–12]. Additionally, recent studies have shown that metalloproteases are present in extracellular vesicles (EVs), such as exosomes [13]. We have shown that EV-bound MMP-3 was transferred into recipient cell nuclei and promoted the tumorigenesis and metastasis of colon cancer cells [11, 14]. Consistent with the pro-tumorigenic roles of a broad range of MMPs, a pan-metalloprotease inhibitor, BB-94, inhibited tumor growth, invasion, and metastasis in human colon, liver, breast, and prostate cancers in mouse models [15, 16].

Moreover, intracellular roles of MMPs have been uncovered, and research on this new aspect of their biology has expanded [17–19]. For example, glycogen synthase kinase-3beta (GSK-3 β) is activated by MMP2-mediated proteolysis in cardiomyoblasts [20]. MMP-3 activated caspase-9 and cleaved Apaf-1, leading to apoptosis [21]. Notably, it has been shown that some MMP members translocate into the nucleus, where they control gene transcription [17, 22]. MMP-3 transcriptionally activates the cellular communication network factor 2 (*CCN2*), aka connective tissue growth factor (*CTGF*) [14, 23], and heat shock protein 70 (*HSP70*) gene in collaboration with heterochromatin protein 1 (HP1) [24]. In addition, nuclear MT1-MMP regulated the PI3K δ /Akt/GSK3 β -Mi-2/NuRD-dependent control of macrophage immune function [25]. Moreover, nuclear MMP-12 mediated *NFKBIA* transcription, leading to IFN- α secretion and host protection in antiviral immunity [26]. Recently, it has been implicated that MMPs regulate epigenetics by cleaving histone tails. MMP-9 facilitated selective proteolysis of the histone H3 tail at genes necessary for proficient osteoclastogenesis [27]. Similarly, MMP-2 mediates ribosomal RNA transcription by cleaving nucleolar histones [28]. Therefore, the intranuclear proteolysis by MMPs may also largely alter cancer progression. However, the nuclear substrates of MMP-3 have not been well investigated. In this study, we performed proteomic analysis to screen nuclear substrates of MMP-3 and found that MMP-3 cleaves nuclear Lamin A (LMNA), which is co-secreted with autophagic EVs in metastatic cancer.

Extracellular vesicles (EVs) are small lipid-bilayered particles sized between 30 nm and 10 μ m secreted by cells, while major EVs, such as exosomes and microvesicles, are sized between 30 nm and 500 nm [29, 30]. EVs carry cell-derived cargo molecules, such as proteins, nucleic acids, and metabolites, inside or on their surface. EVs with cargo molecules are found in body fluids, such as serum, saliva, and urine, as well as in cell/tissue culture supernatants. Therefore, some EV cargo molecules have been developed as prognostic biomarkers of diseases, including cancers, and of pathophysiological body states. For example, we have shown that epithelial cell adhesion molecule (EpCAM) and heat shock protein 90 (HSP90), including HSP90 α , HSP90 β , and TRAP1/HSP75, are enriched in lymph-node-metastatic HNSC-EVs and indicate poor prognosis of HNSCs [31–33]. Notably, EV-mediated intercellular molecular transfer is essential for intercellular communication [34, 35]. Via the molecular transfer, cancer cell-derived EVs arrange tumor-associated cells in the TME and distant cells to form a metastatic niche [30, 36, 37]. We have also shown that HNSC-derived HSP90-bearing EVs initiate EMT, promote cancer cell migration, invasion, and stem cell-like properties, and polarize tumor-associated

macrophages (TAM) into tumor-supporting M2-type [38, 39]. Among various EV types, exosomes are secreted from cells via exocytosis, in which multivesicular bodies (MVBs) that contain intra-luminal vesicles (ILVs) fuse with the plasma membrane and exocytose exosomes [29, 30]. Additionally, recent studies have identified the autophagic EV secretion pathway in which the fusion of autophagosomes and MVBs generates amphisomes, which then fuse with the plasma membrane and secrete dozens of protein types and RNAs via exosomes, which is also known as exophagy [30, 40–42]. EVs have often been separated in monolayer cell culture systems, whereas three-dimensional (3D) tumoroids, also known as cancer organoids that mimic in vivo tumors, have been applied to EV studies [11, 43]. Notably, we recently reported that MMP-3 is essential for the integrity of cancer EVs, promoting 3D tumor growth in vitro by inhibiting necrosis, whereas MMP-3 knockout in EVs significantly inhibited their pro-tumorigenic role in the 3D tumoroid culture model [11]. However, it remains unclear whether MMP-3 controls key protein expression in cancer EVs. Here, we aimed to discover key proteins controlled by MMP-3 in EVs. Surprisingly, Lamin A was detected in metastatic cancer EVs, and MMP-3 controlled its cleavage and autophagic EV secretion.

Lamins are nucleo-skeletal proteins supporting the nuclear envelope (NE) from inside. In human cells, A-type lamins (Lamin A, Lamin C, and minor isoforms) are expressed in a tissue- and development-specific manner, while B-type lamins (B1 and B2) are ubiquitously expressed [44]. Changes in Lamin A/C levels are associated with a poor prognosis in multiple human cancers [45]. Lamin A/C controls many cellular processes with key roles in cancer, including cell invasion, stemness, genomic stability, signal transduction, transcriptional regulation, and resistance to mechanical stress [45]. While the dynamic cytoplasm deforms easily to fit through micron-scale spaces, the nucleus supported by Lamins is the largest and stiffest cellular organelle, and nuclear deformation can impose a rate-limiting step on migration [46, 47]. Notably, increasing evidence suggests that nucleophagy, a selective form of autophagy that targets nuclear components such as Lamins, plays a critical role in preserving nuclear integrity by clearing dysfunctional nuclear materials [48]. We therefore hypothesized that MMP3 cleavage of Lamin A induces nuclear deformity and nucleophagy in metastatic cancer cells. In the present study, we indeed show that MMP3 cleavage of Lamin A induces nuclear deformity, which is required for increased migration in confined spaces and nucleophagy leading to autophagic EV secretion in metastatic cancer cells.

Materials and methods

Cellular cloning

MMP3-knockout LuM1 cells were generated using a CRISPR/Cas9-based genome-editing technology as described previously [14]. Cloning of cells expressing palmitoylation signal-fused (membrane-bound) green fluorescent protein (pGFP) was performed as described previously [11, 38]. Lentiviral reporter constructs of CSCW-palmitoylation signal-EGFP were kindly gifted from Dr. Charles P. Lai [49]. For virus production, HEK293T cells at 70–80% confluence were transfected with the construct, psPAX2 packaging plasmid, and pMD2.G envelope plasmid using PEI max (Polysciences, Warrington, PA, USA). HSC-3-M3 (M3) and LuM1 cells were infected by using the spinfection method with the viral solution. Infected/transduced stable cells were selected using puromycin. Single clones were isolated by the limiting dilution to establish M3pGFP cells and LuM1pGFP cell lines.

Cells and tumoroid culture

Colon26 (aka CT26), LuM1, LuM1/MMP3-KO, and LuM1pGFP cells were maintained in RPMI1640 media with 10% fetal bovine serum (FBS), penicillin, streptomycin, and amphotericin B [12]. HSC-3-M3/pGFP (M3pGFP), HEK293, COS-7, and HeLa cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% FBS, penicillin, and streptomycin. For autophagy-inducing starvation, cells were cultured in serum-free, amino acid-free DMEM (FujiFilm Wako, Osaka, Japan) for 3 h.

Tumoroids of LuM1 and LuM1/MMP3-KO cells were formed in the 3D culture systems using ultra-low attachment (ULA) culture plates/dishes (Greiner, Kremsmunster, Austria) within mTeSR1 stem-cell medium (StemCell Technologies, Vancouver, BC, Canada) as described previously [43, 50, 51].

For immunoelectron microscopy (immunoEM) of EV particles, LuM1 cells were cultured in a half-and-half medium of serum-free RPMI and Essential 8 xeno-free, serum-free defined medium (Thermo Fisher Scientific/Gibco, Waltham, MA, USA) containing DMEM/F12, bFGF, TGF β , insulin, transferrin, selenium, and ascorbic acid.

Plasmid constructs

Plasmid pcDNA3.1/MMP3-GFP with a N-terminal signal peptide and a C-terminal GFP tag was constructed using TOPO technology as described previously [24]. MMP-3 truncated constructs, including full-length (FL), catalytically dead (Cat-Dead), active form (Act), catalytic domain (Cat), and hemopexin-like repeat domain (PEX), with N-terminal 3 \times Flag and C-terminal myc tags without a signal peptide, were constructed as previously described

[23]. The GFP-Lamin-A plasmid (206027) was obtained from Addgene.

Transfection

Cells were cultured in 6-cm dishes and transiently transfected with plasmids using Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's instructions. Stable transfected cell cloning was performed as described previously [52]. Briefly, pcDNA3.1/MMP3-GFP or pcDNA3.1 plasmids were transfected into HeLa cells using Lipofectamine 2000. Cells were selected within 0.2, 0.4, 0.8, and 1.6 μ g/mL of geneticin for 2 weeks to establish stable clones.

Separation of EVs and non-EV fraction

EVs were prepared from culture supernatants of 3D-cultured tumoroids [11] or monolayer cells using the modified polymer-based precipitation (mPBP) method combined with the centrifugation filter method (PBP-CF) [38, 43, 53]. For proteomics, LuM1 cells were seeded on a 10-cm ultra-low attachment (ULA) dish at a density of 1.0×10^6 cells/8 mL mTeSR1 medium and cultured for six days. Tumoroids were washed with phosphate-buffered saline (PBS) and cultured in mTeSR1 medium (4 mL per dish) for two days. The cell culture supernatant was collected and centrifuged at $2000 \times g$ for 30 min at 4 $^{\circ}$ C to remove the detached cells and cell debris. The supernatant was then centrifuged at $10,000 \times g$ for 30 min at 4 $^{\circ}$ C to remove far larger EVs. The supernatant (8 mL) was concentrated to less than 1 mL using an Amicon Ultra-15 centrifugal filter device for M.W. 100k (Merck Millipore, Burlington, MA). The pass-through was used for the non-EV fraction, and the concentrate was used for the EV fraction. The concentrate was applied to the same volume of total exosome isolation reagent (Thermo Fisher Scientific) and incubated overnight at 4 $^{\circ}$ C. The mixture was centrifuged at $10,000 \times g$ for 60 min at 4 $^{\circ}$ C. The pellet was dissolved in 100 μ L phosphate-buffered saline (PBS) by vortexing. The pass-through was concentrated using an Amicon Ultra-15 centrifugal filter device for M.W. 10k (Merck Millipore) and used as non-EV fractions. The protein concentration was measured using a micro BCA protein assay kit (Thermo Fisher Scientific).

For ImmunoEM, LuM1 cells were cultured in six 15-cm dishes, each containing 10 ml of Essential 8/RPMI half-and-half medium per dish without serum. Cell culture supernatants were collected three times at every 2-day intervals during the proliferating, confluent, and over-confluent phases three times. The culture supernatant was centrifuged at $300 \times g$ for 5 min at 4 $^{\circ}$ C to remove cells. The supernatant was centrifuged at $1200 \times g$ at 4 $^{\circ}$ C for 20 min to remove cell debris. The supernatant was then centrifuged at $10,000 \times g$ for 30 min at 4 $^{\circ}$ C. The supernatant was concentrated using two Amicon

Ultra-15 centrifugal Filter Devices for M.W. 100k (Merck Millipore) by centrifuging at $5000 \times g$ for 10 min in a fixed-angle rotor, repeating several times until the concentrate was reduced to less than 500 μL . The same volume of total exosome isolation reagent (Thermo Fisher Scientific) was added to the concentrate, and the mixture was incubated at 4 °C overnight. The mixture was centrifuged at $10,000 \times g$ for 60 min at 4 °C. The pellet was dissolved in 100 μL PBS by vortexing.

Transmission electron microscopy (TEM)

TEM grids, i.e., formvar/carbon-supported copper grids with a grid size of 400-mesh grid size, were hydrophilically treated. The EV suspensions (5–10 μL each) were placed on Parafilm. The grids were floated on the EV suspension for 15 min. Samples were treated with 2% uranyl acetate solution for negative staining for 2 min and visualized at 5,000, 10,000, or 20,000 times magnification with an H-7650 TEM (Hitachi, Tokyo, Japan) at the Central Research Laboratory, Okayama University Medical School.

Immuno-electron microscopy (ImmunoEM)

EVs were bound to TEM grids as described above. The EV samples were blocked in 1% BSA and 10% goat serum in PBS for 15 min and then treated with primary antibodies to Lamin A/C (4777s, Cell Signaling Technology, Danvers, MA, USA; 1:25), cleaved Lamin (2035s, Cell Signaling Technology; 1:100), EpCAM (2929s, VU1D9, mouse mAb, Cell Signaling Technology; 1:800) and MMP-3 (ab52915, rabbit monoclonal, Abcam, Cambridge, United Kingdom; 1:25) in the blocking buffer overnight at 4 °C. No primary antibody was used for the negative control study. Samples were washed 5 times in 0.1% bovine serum albumin (BSA) in PBS and then treated with 10-nm colloidal gold particle-conjugated anti-mouse goat IgG or anti-rabbit goat IgG (BBI solutions, Crumlin, Wakes, United Kingdom; 1:50) secondary antibodies for 2 h at room temperature (RT). Samples were washed with 0.1% BSA in PBS 3 times and 0.1% PBS once, fixed with 2% glutaraldehyde for 3 min, and washed with distilled water once. Samples were treated with 0.3% uranyl acetate and visualized at $\times 30,000$ or $\times 50,000$ magnification with an H-7650 TEM (Hitachi, Tokyo, Japan) at the Central Research Laboratory, Okayama University Medical School.

Particle diameter distribution

The particle diameters of the EV fractions in the range of 0–6000 nm were analyzed using a Zetasizer Nano ZSP (Malvern Panalytical, Malvern, UK).

Immunoprecipitation (IP)

IP was performed as described previously [23]. MMP3-GFP overexpressed cells were treated with heat shock stress (HSS) at 43 °C for 30 min, 5 min, or left untreated. Nuclear extracts were collected from the MMP3-GFP/non-heat, MMP3-GFP/HSS, and HeLa/pcDNA3.1/non-heat cells using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific). Alternatively, cell lysates were prepared using CellLytic M (Sigma). Co-IP was performed using Dynabeads Co-IP kit (Thermo Fisher Scientific) with anti-GFP (ab290, Abcam) and anti-HSP90 (4874, Cell Signaling Technology) antibodies. The co-precipitated proteins were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in 4–20% TGX-GEL (BioRad, Hercules, CA, USA), Coomassie Brilliant Blue (CBB) staining, and mass spectrometry (MS).

For analysis of MMP-3 oligomers, a plasmid 3 \times Flag-MMP3-myc was transfected into COS7 cells. Protein complexes were precipitated using a FLAG IP kit (Sigma-Aldrich, St. Louis, MO, USA) with anti-Flag M2 antibody-conjugated magnetic beads. The protein complexes were analyzed by western blotting using the C-terminal myc tag.

Mass spectrometry (MS)

Liquid chromatography and tandem mass spectrometry (LC-MS/MS) were performed as described previously [31, 53, 54]. Gel fragments containing the stained protein bands were excised from the CBB staining and minced into 1×1 to 2×2 mm pieces. The proteins were digested using an In-Gel Tryptic Digestion Kit (Thermo Fisher Scientific). The gel pieces were destained with a mixture of ammonium bicarbonate and acetonitrile. The protein samples were reduced with 50mM Tris [2-carboxyethyl] phosphine (TCEP), and alkylated with iodoacetamide (IAA). To shrink gel fragments, acetonitrile was added and incubated for 15 min at RT; after which the acetonitrile was removed and the gel pieces were air-dried for 5–10 min. Ten microliters of MS-grade trypsin (Pierce, Thermo Fisher Scientific) at a concentration of 0.1 mg/mL was added to the air-dried sample, and the mixture was incubated at RT for 15 min. Ammonium bicarbonate at a final concentration of 25 mM was added to the sample, digested overnight at 30 °C, and the extract was recovered. Subsequently, a 1% formic acid solution was added to the gel pieces, which were incubated for 5 min, and the supernatant was added to the extract. Extracts containing digested peptides were measured by an LC/MS system, Agilent 1100LC/MSD Trap XCT Ultra (Agilent Technologies, Santa Clara, CA, USA) with the MASCOT database search engine at the Central Research Laboratory, Okayama University Medical School for EV samples and at the Taplin Biological Mass Spectrometry

Facility at Harvard Medical School for IP samples. The scores were defined based on the coverage rate for amino acid sequences and the frequency of detected fragments. The MS and MS/MS data were analyzed by the data analysis software Spectrum Mill (Agilent Technologies). The cutoff score for proteins was 8.0. Protein types detected in each EV fraction were classified by biological function and compared using MS scores. A heat map was generated using GraphPad Prism (GraphPad Software, Boston, MA, USA).

Protein-protein interactions map

Protein-protein interactions were analyzed using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) v12 [55]. Briefly, the proteins identified by LC-MS/MS were classified into 3 classes: nuclear proteins (histones, transcription factors, chromatin regulators, splicing factors, and topoisomerases); nucleocytoskeletal, cytoplasmic and exosomal proteins; and ribosomal and translational proteins. The proteins in each class were input into the STRING. The nuclear proteins were further subclassified.

Protease cleavage site prediction

The MMP cleavage sites were predicted based on the combination of peptide fragments obtained by LC-MS/MS, band sizes of Lamin A/C in CBB staining, and amino acid sequences in a previous study [56].

Western blotting (WB)

Western blotting was performed as described previously [11, 24, 52, 57]. For tumoroids and their EVs, LuM1 cells were cultured for 6 days in a 6-well ULA plate at a density of 3.0×10^5 cells per well in 3 mL mTeSR1 medium. Cells were further cultured in serum-free media for 2 days. On day 8, the supernatants and tumoroids were collected and centrifuged at $2000 \times g$, 4°C for 5 min. Cell culture supernatant was used to separate EV and non-EV fractions as described above or directly concentrated using an Amicon Ultra centrifugal Filter Device (Merck Millipore). To prepare the whole cell lysates (WCL), tumoroids or monolayer cells were lysed in a RIPA buffer (1% NP-40, 0.1% SDS, 0.5% deoxycholate, and EDTA-free protease inhibitor cocktail in PBS) using 25-gauge syringes. Cell lysates were incubated on ice for 30 min, then centrifuged at $12,000 \times g$ for 20 min at 4°C . The supernatant was used as a soluble cell lysate. The pellet was used as a chromatin fraction. The nuclear and cytoplasmic fractions were extracted using NE-PER nuclear and cytoplasmic extraction reagent (Thermo Fisher Scientific). For SDS-PAGE, the same amount of protein was loaded into each lane. EV and WCL samples (10 μg per lane) and non-EV fractions (5 μg per lane) were loaded. Proteins were transferred to a polyvinylidene fluoride (PVDF)

membrane using a semi-dry transfer system. The membranes were blocked in 5% skim milk in Tris-buffered saline (TBS) containing 0.05% Tween 20 for 60 min at RT and then incubated overnight with primary antibodies to MMP-3 (EP1186Y, ab52915, Abcam), Lamin A/C (CST4777s, Cell Signaling Technology), cleaved Lamin (CST2035s, Cell Signaling Technology, rabbit polyclonal), CD63 (EXOAB-CD63A-1, System Biosciences, Palo Alto, CA, USA; rabbit polyclonal), GFP (ab290, Abcam), FLAG-tag (F3165, Sigma-Aldrich), myc-tag (9E10, ab32, Abcam), and GAPDH (5174, Cell Signaling Technology). For CD63, the membrane was blocked in 10% skim milk overnight and incubated with the primary antibody for 2 days. The membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies. Blots were visualized with the ECL substrate (Merck Millipore).

Immunocytochemistry (ICC)

ICC was performed as previously described [23, 52]. For overexpression studies, COS-7 or HeLa cells were cultured on 120-mm round coverslips coated with a poly-D-Lysine/Laminin coating (BD Bioscience, Franklin Lakes, NJ, USA) in 35-mm dishes. Cells were transfected with plasmids. Cells were fixed with 4% paraformaldehyde (PFA) for 10 min and washed twice with PBS. Cells were permeabilized with 0.1% Triton X-100 for 10 min and washed twice with PBS. Cells were incubated in a blocking buffer containing 3% normal goat serum in PBS for 30 min, then primary antibodies at 4°C overnight, followed by secondary antibodies at RT for 1 h in the blocking buffer. Cells were washed three times with PBS for 5 min between the steps. Cells were mounted within ProLong Gold Antifade Mountant with 4',6-diamidino-2-phenylindole (DAPI) (Thermo Fisher Scientific). Fluorescence images were acquired using the AxioVision fluorescence microscope (Zeiss, Oberkochen, Germany) with a camera AxioCam MR3 (Zeiss) and a filter set for DAPI, GFP, Cy3.5 (excitation wavelength: 580 nm), and Cy5 (excitation wavelength: 650 nm). Primary antibodies to GFP (ab290, Abcam), cleaved Lamin (CST2035s, Cell Signaling Technology), Myc-tag (9E10, ab32, Abcam), and Flag-tag (M2, Sigma-Aldrich) were used. Alexa Fluor 350, 488, 594, and 648 secondary antibodies (Thermo Fisher Scientific) were used.

Alternatively, LuM1, Colon26, and MMP3-KO cells were cultured in 8-well chamber slides (#354118; Falcon, Corning, NY, USA) for a few days. Cells were washed with PBS and fixed in 4% PFA for 10 min. Cells were washed three times with cold PBS for 3 min each. Cells were permeabilized with 0.2% Triton X-100 for 10 min and washed three times with PBS for 3 min. Cells were blocked with Blocking One Histo (Nacalai Tesque, Kyoto, Japan) for 10 min and washed with PBS

for 5 min. Cells were incubated with primary antibodies to MMP3 (Abcam, EP1186Y, ab52915, rabbit monoclonal, 1:200), Lamin A/C (Cell Signaling Technology, #4777s, mouse monoclonal, 1:200), CD63 (Santa Cruz, sc-5275, MX-49.129.5, mouse monoclonal, 1:100), and LC3B (Cell Signaling Technology, #3868, D11, rabbit monoclonal, 1:1600) in 1:20-diluted Blocking One Histo in PBS overnight at 4°C. Cells were washed with PBS for 3 min 3 times. Cells were incubated with AlexaFluor 488, 594, or 647 secondary antibodies to rabbit or mouse IgG (1:500) in 1:20-diluted Blocking One Histo in PBS for 1 h at RT. Cells were washed with PBS for 3 min 3 times. Cells were mounted on DAPI-containing mounting medium with cover glasses, and sealed with manihure. Fluorescent images were taken using the LSM780 confocal laser scanning microscope (CLSM) (Carl Zeiss, Oberkochen, Germany) at the Central Research Laboratory, Okayama University Medical School, with a $\times 63$ oil immersion lens, and using the BZ-X800 all-in-one fluorescence microscopy (Keyence, Osaka, Japan) with a $\times 60$ oil immersion lens and $\times 2$ digital zoom.

Confocal images were taken using the LSM780 with diode laser (405 nm, blue), argon laser (488 nm, green), HeNe laser (594 and 633 nm, red and far red), 1- μm section, pinhole 65–70, averaging number 8, and size setting 1280 \times 1280 pixels. The 405-nm laser was applied with a master gain of 650–800, and power 2. The 488-nm laser was applied with a master gain of 900–1200 and power 2. The 594 and 633-nm lasers were applied with gain 1250 (max), digital gain 1–15, digital offset –32 to –320, and power 2–15. Brightness, contrast, gamma value, pseudocolors, and image merge were edited using ZEN 3.0 SR black edition (Carl Zeiss).

Haze reduction and 3D images were generated using the BZ-X800. Resolution sensitivity was customized as gain $\times 4$ –8 (12–18 dB) and binning 2 \times 2. Z-stack images were acquired in sectioning mode with a 0.2–0.4 μm pitch. Levels, brightness (120–200), and contrast (0–80) were manually adjusted for overlay. 3D images were created. Full-focused images were generated, and haze reduction was processed with settings of blur size (4–8), brightness (3–20), reduction rate (0.9–1.2), and noise removal. Images of tumoroids were taken in quick full-focus mode with haze reduction set to 3 and weak edge.

Quantitative immunocytochemistry (qICC)

For qICC, three fields-of-view ICC images were taken using the BZ-X800 microscope (Keyence) with $\times 20$ and $\times 40$ lenses and analyzed using the hybrid cell count tool in a BZ-X800 analyzer (Keyence). To quantify DNA area and content, images of DAPI staining were taken with an exposure time of 1/35 sec and processed with a threshold of 10. Lamin A/C images were acquired with an exposure time of 1.5 s and processed with a threshold of 130 and

cut-off values ($< 50 \mu\text{m}^2$ and $> 500 \mu\text{m}^2$) to exclude unfocused and aggregated cells. MMP-3 images were captured with an exposure time of 10 s and processed with a threshold of 25 and background subtraction of 45,000. For expression correlation analysis, ICC images were taken with exposure time of 1/3.5 s (Lamin A/C), 3 s (MMP-3) and 1/80 sec (DAPI), weak edging, haze reduction setting 2, and quick full focus mode, and analyzed with threshold of 100 (MMP-3), 35 (Lamin A/C), and 12 (DAPI), gap filling 0–10, and area separation 90–100. Correlations in MMP-3-positive cells were analyzed.

Scratch assay (wound healing assay)

Cells were cultured in an 8-well chamber slide or a 12-well plate until over-confluent. Cellular sheets were scratched using a 1-mL pipette tip. Images of 4–10 fields of view were captured at 0 and 4 h after the scratch, using the BZ-X800 (Keyence) with $\times 4$ lens, oblique illumination, 40% aperture, 75–100% transmission light, 1/2250–1/5500 sec of brightness (exposure), weak edging, and HR setting 3. The blank areas without cells were measured using the BZ-X800 analyzer. Migration speed was calculated with the following formula.

$$\text{Migration speed} \left(\frac{\mu\text{m}}{\text{h}} \right) = \frac{\text{Blank area (0h, } \mu\text{m}^2) - \text{Blank area (4h, } \mu\text{m}^2)}{2 \text{ (both side)} \times \text{time (h)} \times \text{height (2710 } \mu\text{m)}}$$

Transwell migration assay

RPMI medium containing 10% FBS (200 μL /well) was added to a 96-well plate. Cells in the same medium were seeded at a concentration of 2×10^4 cells/100 μL /well in the upper chamber of the HTS Transwell-96 well plate 8 μm (pore size) polyester membrane (Corning, Corning, NY) and cultured for 22 h. The cells were stained with Diff-Quik (Sysmex, Kobe, Japan) by fixing in 100% methanol for 10 s, staining with eosin for 20 s, and staining with methylene blue and azull for 20 s. Microphotographs were taken using Keyence BZ-X800 with $\times 4$ and $\times 10$ lenses.

Alternatively, 1×10^6 detached cells/ml (serum-free RPMI) were incubated with 0.1 μM (1:1000) Mito-Bright LT Red (Dojindo, Kumamoto, Japan) at 37 °C for 30 min. Cells were diluted 10-fold by mixing 100 μL of cells and 900 μL of serum-free RPMI. Cells were seeded at a concentration of 1×10^4 cells/100 μL /well in the upper chamber of the HTS Transwell-96 well plate (Corning, Corning, NY) and cultured for 22 h. Red fluorescence microphotographs were taken using a Keyence BZ-X800 with a $\times 4$ lens, 100% excitation light, 1.5 sec exposure time, and appropriate black balance. Numbers and areas of migrating cells were quantified using the Hybrid Cell Count on the BZ-X700 analyzer (Keyence, Osaka, Japan). The threshold was set between 100 and 300. Signals below $100 \mu\text{m}^2$ were omitted.

Immunohistochemistry (IHC)

Twenty OSCC tissues (stage I, non-metastatic: $n=10$, stage IV, metastatic: $n=10$) resected at Okayama University Hospital Oral Surgery were examined. IHC was performed as described previously [11, 12, 38]. Paraffin blocks of specimens were cut at 3- μm thickness. The sections were deparaffinized and hydrated through xylenes and graded alcohol series. Antigen retrieval was performed by autoclaving in 0.01 M citrate buffer pH 6.0 (sodium citrate dihydrate, citric acid; Sigma-Aldrich, USA) in a pressure cooker for 8 min. Sections were treated with blocking solution (Dako, Glostrup, Denmark) for 30 min at RT, then incubated with primary antibodies to MMP-3 (ab52915, Abcam) and cleaved Lamin (CST2035s, Cell Signaling Technology) at 4 °C overnight. Sections were subsequently incubated with secondary antibodies: goat anti-rabbit IgG Alexa Fluor 488 and anti-mouse IgG Alexa Fluor 594 (Thermo Fisher Scientific) for 1 h at RT. Fluorescent images were taken using a BZ-X810 Fluorescence Microscope (Keyence, Osaka, Japan). MMP3-positive nuclei, cleaved Lamin-positive nuclei, and double-positive nuclei were counted in 300 cells in each case.

Pan-cancer gene expression analysis

Pan-cancer mRNA expression of *MMP3* and *LMNA* was analyzed using the Human Protein Atlas (HPA) [58, 59].

Kaplan-Meier analysis

Kaplan-Meier (KM) survival curves of patient groups with high- vs. low-expression in various types of cancers at various stages were analyzed using the KM plotter with TCGA database [59, 60].

Co-expression correlation analysis

Co-expression correlation of *LMNA* and *MMP3* in patient-derived tumors was analyzed using cBioPortal [59, 61]. Head and neck squamous cell carcinoma (TCGA, PanCancer Atlas) samples (496 samples/patients) and pancreatic adenocarcinoma (TCGA, PanCancer Atlas) samples (175 samples/patients) were analyzed.

Statistical analysis

Analysis of the statistical significances and generation of graphs were performed using Prism 8 (GraphPad Software) and Excel (Microsoft). Two groups were compared using an unpaired or paired *t*-test, where appropriate. Three groups were compared using one-way analysis of variance (ANOVA). For KM analysis, statistical significances was assessed using the log-rank test, and log-rank *p*-values and hazard ratios (HRs) were calculated using KM plotter. Statistical significance was set at $p < 0.05$.

Data were expressed as mean \pm S.D. unless otherwise specified.

Results

MMP-3 regulates the secretion of Lamin A/C with extracellular vesicles in metastatic cancer

We first separated EVs secreted by MMP3-high and MMP3-KO LuM1 colon cancer tumoroids (Fig. 1A). Notably, MMP3-KO tumoroids were more necrotic than MMP3-high tumoroids [11]. Small EVs (50–200 nm) and large EVs (500–1000 nm) were found in the culture supernatants of MMP3-high tumoroids and MMP3-KO tumoroids (Fig. 1B, C; Figure S1). Aggregated EVs were also found (Fig. 1B). MMP3 KO induced a loss of small EVs and an increase of large EVs (Fig. 1C, D). EV proteome analyses revealed that the MMP3-high EVs were enriched with intermediate filament proteins such as Lamin A/C (LMNA and LMNC) and Vimentin (VIM), proteases such as MMP-3, MMP-10 and trypsin-like serine protease, ECM proteins such as fibronectin (FN) and secreted phospho-protein (SPP1 aka. OPN or BSP), cytoskeletal proteins such as actins (β and γ) and plectin, HSPs such as Hsp70 homologs, Hsc70 and Grp78 (aka. HspA5 or Bip), kinases such as pyruvate kinase M (PKM) and phosphoglycerate kinase (PGK), ferritin light chain (FTL), myosin heavy chain 9, proteasome subunits A1 and B7, viral protein Gag-Pol, hemogen, RAN, enolase (ENO1), alpha fetoprotein (AFP), and formin-binding protein (FNBP1) (Fig. 1E, F, G). Notably, the levels of most of these EV proteins were markedly reduced by MMP3 KO (Fig. 1E, G). The significant loss of Lamin A/C by MMP3 KO was confirmed by triplicate MS experiments, indicating that MMP-3 positively regulates Lamin A/C secretion with EVs from LuM1 colon cancer tumoroids (Fig. 1H). Consistently, gene expression levels of *MMP3* and *LMNA* were positively correlated in clinical tumor specimens of HNSC (Pearson correlation coefficient: 0.30, $p = 1.41\text{e-}11$) and pancreatic adenocarcinoma (Pearson correlation coefficient: 0.35, $p = 3.788\text{e-}6$) (Figure S2).

We next examined whether MMP3 KO altered the levels of cleaved Lamin and EV marker CD63 in EVs. MMP-3 mature forms were found in EVs and non-EV fractions secreted by MMP3-high tumoroids, whereas MMP-3 was totally lost by the KO (Fig. 1I, Figure S3). Cleaved Lamin was detected in EVs and in the non-EV soluble fraction of MMP3-high tumoroids, although this was reduced in MMP3 KO tumoroids. CD63, found in EVs, was also decreased by MMP3-KO.

ImmunoEM confirmed the existence of extracellular Lamin A/C secreted by LuM1 cells (Fig. 1J, Figure S4, Figure S5). EV-bound Lamin A/C and vesicle-free Lamin A/C were found to be secreted by LuM1 cells (Fig. 1J,




Fig. 1 MMP-3 regulates the secretion of Lamin A/C with extracellular vesicles is regulated by MMP-3 in metastatic cancer. **A** An experimental design to compare EV proteomes of MMP3-high and MMP3-KO LuM1 tumoroids. **B** TEM images of EVs. s-EV, small EVs; L-EVs, large EVs; a-EV, aggregated EVs. Scale bars, 200 nm. **C** Particle diameter distribution analysis. **D** Rate of s-EV and L-EV particles in total particles. $n = 3$ EV samples, $*p = 0.025$ (paired t-test). Data were expressed as means \pm S.E.M. **E** Venn diagram of representative protein types in EVs. **F** EV protein classification with summed mass spectrometry (MS) scores. **G** Heat map of EV protein types, whose expression levels were altered by MMP3-KO. **H** Relative MS scores of Lamin A/C in LuM1 tumoroid-EVs and MMP3-KO. $n = 3$ MS experiments, $**p = 0.0082$ (paired t-test). Data were expressed as means \pm S.E.M. **I** Western blot showing MMP3, cleaved Lamin, and CD63 in EVs and non-EV fractions of MMP3-high and MMP3-KO tumoroids. **J** Representative immunoelectron microscopy images of Lamin A/C and cleaved Lamin on the surface of EVs released by LuM1 cells. Scale bar, 100 nm

Figure S5). One to four Lamin A molecules were found per particle (30–100 nm).

These data suggest that MMP-3 regulates the secretion of Lamin A/C with EVs in metastatic cancer.

MMP-3 binds to Lamin A, transcriptional, and splicing factors

Lamin A/C is a nuclear lamina (matrix) protein that controls nuclear structure, signaling, transcription, and chromatin organization [62–64]. Relevantly, our previous studies showed that nuclear MMP-3 regulated transcription by binding to HP1 α/γ , also known as the chromobox proteins (CBXs) [23, 24]. Moreover, nuclear MMP-3 activation of the *HSP70* gene was enhanced by heat shock factor 1 (HSF1) and heat shock stress (HSS) [24]. Therefore, we hypothesized that nuclear MMP-3 interacted with various nuclear proteins to regulate nuclear events, including Lamin A/C processing. We thus pursued a mechanism by which MMP-3 controlled the secretion of cleaved Lamin A.

To explore the intranuclear MMP3-interacting proteins and substrates, we employed a proteomic approach combining co-IP and LC-MS/MS. It was shown that MMPs were activated without the removal of N-terminal pre-pro-domains [65]. Therefore, we first overexpressed MMP-3 in cells with an N-terminal signal peptide and a C-terminal GFP tag. MMP3-GFP was found not only in culture supernatant but also in cell lysate, indicating intracellular MMP-3 to be overexpressed (Fig. 2A). Then, stable MMP3-expressing cells were cloned. To characterize the nuclear MMP3-binding proteins, we collected the nuclear extracts from MMP3-overexpressing cells treated with HSS, untreated, and negative control cells transfected with an empty vector and then performed co-IP and LC-MS/MS analysis (Fig. 2B, C). CBB staining indicated a ladder of cofactors, including significant triplet bands of histones on the bottom, bound with MMP-3, whereas bands were not found in the negative control empty vector and HSS cells (Fig. 2C, left), suggesting that 30-min HSS canceled MMP-3 interactions with cofactors and substrates. LC-MS/MS identified a diverse range of MMP3-binding proteins, including Lamin A (LMNA) fragments and oligomers (Table 1, Figure S6), histones, DNA topoisomerase II (Top2A and Top2B), heterogeneous nuclear ribonucleoproteins (hnRNPs), filamins, BAZ2B (bromodomain adjacent To zinc finger domain 2B), ribosomal proteins, spectrin, and HP1/CBXs (Fig. 2C, D). The native molecular weight of Lamin A is 70 kDa, whereas several fragments with different molecular weights (35k, 30k, 22k, 18k, 13k, and 11k) and potential oligomers (145k and 130k) were bound with MMP-3 (Fig. 2C, Figure S6, Table 1), suggesting that MMP-3 could first bind to Lamin A/C oligomer filaments and then processed them into short fragments.

To further explore the substrate proteins of MMP-3, we overexpressed MMP-3, treated cells with a short HSS at 43 °C for 5 min, and co-immunoprecipitated using an anti-HSP90 antibody, as HSP90 is a key molecular chaperone that controls proteostasis of unfolded and misfolded proteins in cancer [66–68]. The combination of MMP-3 and short HSS generated 30-kDa new fragments of Lamin A, Vimentin, NONO, ATP5A1, nucleolin, and DKC1, which were originally all larger than 30 kDa (Table 2, Figure S7), suggesting that MMP-3 processed these proteins. Notably, Lamin A and Vimentin, which are intermediate filament proteins, were also detected in EVs as well, likely processed and extracellularly transported by MMP-3 (Table 2; Fig. 1G).

Further dry analysis revealed MMP3-interacting proteins categorized into nucleo-cytoskeletal proteins (including Lamin A/C and Vimentin), cytoplasmic and exosomal proteins, histones, topoisomerases, alternative splicing factors, chromatin regulators, transcription factors, and translational/ribosomal proteins (Fig. 2E, F).

These data suggest that MMP-3 binds to nuclear Lamin A oligomers, participates in its processing, and is involved in nuclear events such as chromatin regulation, transcription, alternative splicing, and cytoskeletal control.

Structural analysis revealed the MMP-3 cleavage site in Lamin A

Combinatorial analyses of the molecular weight of Lamin A fragments in CBB staining (Fig. 2C; Table 1) and identified peptide sequences of Lamin A (Figure S6) enabled us to predict rough structures of Lamin A fragments generated by MMP-3. Furthermore, the addition of consensus MMP-3 cleavage sequences shown in a previous study [56] enabled us to predict MMP cleavage sites in the Lamin A structure.

Lamin A is a nuclear structural protein that forms filaments lining the NE (Fig. 3A). A Lamin A monomer comprises distinct domains: a head domain, a coiled-coil domain, an Ig-like domain, and a tail domain in that order from the N-terminus to the C-terminus (Fig. 3B, C). The coiled-coil domain (aka central rod domain) consists of coils 1a, 1b, and 2. The Lamin A monomer undergoes co-translational dimerization, followed by tetramerization and subsequent polymerization to form filaments of the nuclear lamina (Fig. 3D). In our study, N-terminal five peptide sequences in the head and coiled-coil domains of Lamin A were identified in 130 and 145 kDa bands, indicating that Lamin A dimers or tetramers formed via the coiled-coil domain were bound with MMP-3 (Fig. 3C, upper left). Lamin A short N-terminal fragments (11, 13, and 22 kDa) were also bound with MMP-3. Moreover, C-terminal fragments (30, 22, 18, 13, and 11 kDa)




Fig. 2 MMP-3 binds to Lamin A, transcriptional and splicing factors. **A** Western blotting shows the overexpressed MMP-3 with a GFP tag and endogenous MMP-3. **B** The experiment scheme. MMP-3 was overexpressed in HEK293 cells. The cells were either heat-shocked at 43 °C for 30 min or left untreated. Nuclei were extracted and treated with micrococcal nuclease (MNase). Co-immunoprecipitation followed by LC-MS/MS was performed. **C** CBB staining (left) and the list (right) of MMP3-binding proteins identified by LC-MS/MS. The number of peptides identified is shown on the right of each protein within parentheses. Lamin A (LMNA) fragments and potential oligomers were detected in several different-sized bands, as shown in bold. See Table 1 for details. **D** Ranking of protein types by the number of peptides identified as MMP3-binding proteins. (E) Pie chart of protein categories. **F** Protein interaction map of the MMP3-binding proteins generated via STRING

of Lamin A containing the Ig-like and tail domains were predicted to bind with MMP-3 (Fig. 3C, right).

The edges of the predicted sequences, combined with the previous report regarding MMP-3 cleavage sequence [56], enabled us to predict six MMP-3 cleavage sites in Lamin A. Among the predicted sites, 343-REMAEMRA-350 was the most reliable sequence and consistent with the 30-kDa fragment found throughout the study.

Thus, the structural analysis revealed the MMP-3 cleavage site in Lamin A.

Nuclear MMP-3 forms mature dimers via its PEX domains

MMP-3, a zinc-dependent endopeptidase, comprises a N-terminal signal peptide, a pre-/pro-domain, a catalytic (Cat) domain, a hinge region, and a C-terminal PEX domain (Fig. 4A, B). Notably, the human MMP-3 protein sequence harbors six NLSs and a single HP1/CBX binding motif (PxVxL) [23, 24] (Fig. 4B). The catalytic domain of MMP-3 forms the proteolytic active sites by housing a zinc ion coordinated by three histidine residues. However, in the zymogen form, the Pre-Pro-domain fundamentally occludes the active site, maintaining a self-inactivated state, whereas a study has reported that

Table 1 Lamin A (LMNA) oligomers and short fragments were bound with MMP-3

Molecular weight	Form	Unique peptide	Total peptide	Average score	Avg. precursor intensity
145 kDa	Oligomer	2	2	2.95	6.37E+04
135 kDa	Oligomer	2	2	2.60	5.81E+04
130 kDa	Oligomer	1	1	3.07	3.37E+04
35 kDa	Fragment	1	1	4.12	8.47E+04
30 kDa	Fragment	3	3	4.14	4.84E+04
22 kDa	Fragment	3	3	3.60	4.61E+04
18 kDa	Fragment	1	1	4.56	4.17E+04
13 kDa	Fragment	4	5	3.40	4.02E+04
11 kDa	Fragment	3	4	3.63	3.25E+04

MMPs can be activated without the removal of the N-terminal pre-pro domains upon cell stress [65]. Nevertheless, the removal of the pre-pro-domain surely and irreversibly activates MMPs. Moreover, it has been shown that extracellular dimerization of MMPs (MMP2 and MT1-MMP) is essential for their protease activities [69, 70]. Additionally, intracellular active dimers of MMP-3 and MMP-9 were indicated by zymographies of WCL of LuM1 metastatic cancer cells [12].

To investigate the subcellular localization, maturation, and dimerization of MMP-3, we overexpressed various intracellular MMP-3 constructs without the signal peptide and examined their subcellular localization and post-translational maturation. Overexpressed full-length (FL) MMP-3 as well as PEX were detected in both soluble and chromatin fractions (Fig. 4C, Figure S8), indicating that MMP-3 was bound to chromatin in nuclei, consistent with Fig. 2. Overexpression of FL-MMP3 resulted in its initial localization to the cytoplasm, while a mature, shorter form was expressed in nuclei, suggesting that the pre-/pro-domain was removed by proteolytic (auto-) processing in nuclei to activate this enzyme (Fig. 4D). Furthermore, the PEX domain formed dimers within the nucleus, although predominantly monomeric in the cytoplasm, suggesting that PEX-PEX interactions mediate MMP-3 dimerization in the nuclear compartment (Fig. 4E). IP-western blotting analysis confirmed the presence of mature MMP-3 oligomers in nuclei (Fig. 4F).

These data indicate that MMP-3 forms mature oligomers through the PEX-PEX interaction in cell nuclei.

MMP-3 cleaves and co-transport Lamin A

We next examined if MMP-3 bound to, processed, and transported Lamin A. Overexpression of the catalytic domain (Cat) or active form (Act) of MMP-3 increased cleaved Lamin in HeLa and COS7 cells (Fig. 5A, B; Figure S9). To further explore the Lamin A status altered by MMP-3, we performed ICC of N-terminal GFP-tagged Lamin A with MMP-3 truncated forms, including FL, Cat-Dead, Act, and Cat (see Fig. 4B regarding the structures). FL-MMP3 and enzymatically inactive MMP-3 (Cat-Dead) co-localized with Lamin A at the nuclear periphery, indicating their continuous binding without processing (Fig. 5C, left). The catalytic domain and active form of MMP-3 induced nuclear speckle formation of Lamin A, suggesting nucleophagosome formation or Lamin A aggregation upon processing (Fig. 5C, right; Figure S10A). Furthermore, overexpression of active MMP-3 and its catalytic domain tended to decrease the nuclear area, suggesting that MMP-3 could degrade the nuclear lamina and other nuclear proteins such as histones (Fig. 5C, Figure S10B).

To visualize MMP-3 cleavage of Lamin A/C, we next examined co-localization of MMP-3, Lamin A/C, and cleaved Lamin in serum- and amino acid-starved LuM1pGFP and M3pGFP cells. Plasma membrane and other membrane structures in cells were successfully visualized with palmitoylated GFP fluorophore (Fig. 5D, E; Figure S11, S12). MMP-3 was co-localized with Lamin A/C in LuM1pGFP and HSC-3-M3pGFP cells (Fig. 5D, E; Figure S11, S12). Simultaneously, loss and deformity of the Lamina and DNA regions were observed in the MMP-3-positive area, indicating the MMP-3-mediated digestion of Lamin A/C. Cleaved Lamin A and MMP-3 were found in co-speckles in the cytoplasm and nuclear peripheral region, suggesting their co-transport from nuclei to cytoplasm toward the extracellular space (Fig. 5F; Figure S13). Cleaved Lamin A/C was generated in both living cells and dying cells (Fig. 5G–I, Figure S14, S15). While the co-leakage of DNA and cleaved Lamin from nuclei was found in living cells (Fig. 5G), DNA fragmentation was seen in the MMP-3 (+) cleaved Lamin (+) nuclei in potentially dying (apoptotic) cells (Fig. 5H).

Collectively, these findings indicate that MMP-3 cleaves Lamin A and co-transport it from nuclei to

Table 2 Protein fragments were generated by MMP-3 overexpression and short heat shock stress at 43 °C for 5 min. The 30 kDa band analyzed by CBB staining and LC-MS/MS is shown in the supplemental figure

Rank	Symbol	Full-length M.W. (Da)	Band size (Da)	Total peptide	Unique peptide	Avg. score	Avg. Precursor Intensity
1	VIM (Vimentin)	55k, 50k, 45k	30k	69	42	3.78	1.26E+07
2	NONO	54k	30k	66	36	3.37	5.00E+06
3	LMNA (Lamin A)	70k, 65k	30k	37	30	3.3	4.34E+06
4	ATP5A1	50k	30k	37	26	3.95	4.63E+06
5	NCL (Nucleolin)	100k	30k	33	24	3.82	5.14E+06
6	DKC1	60k	30k	36	22	3.44	5.96E+06




Fig. 3 Structural analysis revealed the MMP-3 cleavage site in Lamin A. **A** A scheme of the nuclear structure. Nuclear lamina (dark blue), lining the nuclear envelope, MMP-3 (yellow), and chromatin (right blue) were drawn. **B** Lamin A protein structure modeled using AlphaFold 3. **C** A map of Lamin A fragments co-precipitated with MMP-3. Top, the domain structures of Lamin A. Middle, six fragments (outer boxes) predicted by the peptide sequences (inner boxes) identified by LC-MS/MS and their molecular weights (written on the right) in CBB staining. Fragments cleaved by trypsin and identified by LC-MS/MS were shown as inner boxes. Details are in Figure S6. Putative MMP-3 cleavage sites in Lamin A are shown at the bottom. The site 343-REMAEMRA-350 consists of the 30-kDa fragment. **D** A scheme showing Lamin A filamentous oligomerization and polymerization. Lamin A undergoes co-translational dimerization




Fig. 4 Nuclear MMP-3 forms mature dimers via its PEX domains. **A** The three-dimensional structure of MMP-3, predicted by AlphaFold 3. Signal peptide (SP) (gray), pre/pro-domain (pink), catalytic domain with hinge region (yellow), and PEX domain (blue). **B** The domain structures of native and overexpressed truncated MMP-3. Top: the structure of native MMP-3. Nuclear localization signal (NLS) (red), PxVxL motifs (dark blue) bound by HP1/CBXs. FL, full length. Cat-Dead, a catalytically dead form. Act., active form. Cat., catalytic domain. Truncated forms were tagged with an N-terminal 3xFlag-tag and a C-terminal myc-tag. **C–E** Plasmid constructs were transfected into COS-7 cells, and western blot analyses were performed. Interpretation schemes were drawn on the right of each panel. **C** Overexpressed FL-MMP3 and PEX were detected in both soluble and chromatin fractions. **D** Western blotting showing the FL and mature forms of MMP-3. Cyto, cytoplasm; Nuc, nuclei. **E** Western blotting showing the PEX monomers in the cytoplasm and the PEX dimer in the nuclei. **F** IP-western blotting showing oligomerization of FL and mature MMP-3. MMP-3 was immunoprecipitated using the N-terminal Flag tag. Western blotting was performed using the C-terminal myc tag




Fig. 5 MMP-3 cleaves and co-transport Lamin A/C. **A** Western blotting showing cleaved Lamin A/C generated by MMP-3 catalytic domain (Cat) overexpression. **B** Western blotting showing cleaved Lamin A/C generated by MMP-3 active form (Act) and Cat overexpression. (**C–I**) Representative immunocytochemistry (ICC) images. Scale bars, 10 μ m. **C** GFP-Lamin A (green) and truncated MMP-3 (full-length (FL), Cat-Dead, Act, and Cat) (red) in HeLa cell nuclei. See Fig. 4B regarding the truncated MMP-3 structures. RBBP4, nuclear protein (blue). Arrows indicate co-localization of MMP-3 with Lamin A. **D, E** Lamin A/C and MMP-3 in LuM1pGFP (**D**) and M3pGFP (**E**) cells with serum- and amino acid-starvation (Stv). Arrows indicate the loss and deformity of the Lamina and DNA area in the MMP-3-positive area. Arrowheads indicate loss of Lamin A/C. Membrane structures were labeled with palmitoylated GFP (pGFP). DNA was stained with DAPI (blue). **F** Cleaved Lamin A, MMP3-GFP, and their co-localization (yellow). **G** Cleaved Lamin and MMP-3 in LuM1pGFP (**G, H**) and M3pGFP (**I**) cells. Cleaved lamin was generated in living cells (**G, I**) and dying cells (**H**). Arrows indicate cleaved Lamin and DNA leakage (**G**). Arrowheads indicate DNA fragmentation in the MMP-3 (+) cleaved Lamin (+) nuclei (**H**)

cytoplasm, while MMP-3 cleavage of Lamin A induces the nuclear aggregation of Lamin A.

Autophagosomes and amphisomes transport MMP-3 and cleaved Lamin

In addition to the MVBs and autophagic EV pathway, it has been shown that migrasomes are involved in membrane trafficking and intercellular communications [71, 72]. Besides, tunneling nanotubes (TNTs) or tumor microtubes (TMs) connect cells and serve as direct conduits for intercellular communication [73, 74]. To examine if MMP-3 and cleaved Lamin were secreted via the autophagy-amphisomes-EV pathway, we examined co-localization of an autophagosome marker (LC3B), a MVB marker (CD63), MMP-3, and cleaved Lamin using CLSM. Amphisomes were proven by the co-localization

of LC3B and CD63 in LuM1, LuM1pGFP, and M3pGFP cells (Fig. 6A–C), suggesting that CD63+ILVs are secreted via amphisomes and exophagy. Amphisomes were localized in the cytoplasm and nuclei in unstarved cells (Fig. 6A), whereas in starved cells they moved to the cellular periphery and formed migrasomes (Fig. 6B, Figure S16). Amphisomes were induced by starvation in certain M3pGFP cells (Fig. 6C, Figure S17).

MMP-3 was profoundly co-localized with LC3B+autophagosomes in both starved and unstarved cells, suggesting that MMP-3 is transported via autophagosomes and amphisomes (Fig. 6D–F; Figure S18, S19). LC3B and MMP-3 were co-localized in nuclei, suggesting that nucleophagy took in MMP-3 (Fig. 6E). While MMP-3 localization in CD63+amphisomes was found in unstarved cells (Fig. 6G, Figure S20), MMP-3 was




Fig. 6 Autophagosomes and amphisomes transport MMP-3 and cleaved Lamin. LuM1, LuM1pGFP, and HSC-3-M3/pGFP cells were starved (Stv) by culturing in the absence of serum and amino acids for 3 h, or unstarved (control). Representative confocal laser scanning microscopy (CLSM) images were shown. Scale bars, 10 μm. **A–C** Amphisomes with co-localized LC3B and CD63. Arrows indicate migrasomes (**B**). **(D–F)** MMP-3 localization in LC3B+ amphisomes/autophagosomes. Arrows indicate nucleophagy (**E**). **(G–I)** MMP-3 localization in CD63+ amphisomes (or multivesicular bodies, MVBs). Arrows indicate nucleophagy (**I**). **J–L** Cleaved Lamin localization in CD63+ amphisomes/MVBs (**J, K**) and LC3B+ amphisomes/autophagosomes (**L**). Arrowheads indicate short tunneling nanotubes (tumor microtubes) (**J**). Arrows indicate nucleophagy (**K**)

profoundly co-localized with CD63+ amphisomes upon starvation in LuM1pGFP and M3pGFP cells, suggesting that starvation induced the transport of MMP-3 via amphisomes (Fig. 6H, I; Figure S20, S21).

Cleaved Lamin was markedly co-localized with CD63 at the cellular periphery and TNTs/TMs, suggesting that nucleophagy of Lamin can contribute to the formation of TNTs/TMs and autophagic EVs (Fig. 6J, Figure S22). Interestingly, cleaved Lamin and CD63 were vastly induced in nuclei and cytoplasm upon starvation in LuM1pGFP cells, suggesting that the starvation induced nucleophagy taking in cleaved Lamin (Fig. 6K, Figure S22). Consistently, the induced cleaved Lamin was also co-localized with LC3B upon starvation, indicating the autophagy of cleaved Lamin (Fig. 6L, Figure S23).

These data suggest that starvation induced MMP-3 cleavage of Lamin A/C and their autophagic transport via amphisomes in HNSC and colon cancer cells.

MMP-3 significantly promotes metastatic cancer cell migration in confined spaces

We have shown that the high expression of MMPs is associated with metastatic cancer cell migration in confined spaces (in LuM1 cells) as compared to the low expression of MMPs associated with a low-metastatic and slow migration phenotype (in the parental Colon26 and the *MMP3* knockout cells) [12, 14]. Here, we examined differential migration activities of parental Colon26 cells (MMP-3 low), rapidly metastatic LuM1 cells (MMP-3 high), and LuM1/*MMP3*-KO cells in the 2D scratch assay and the Transwell migration assay.

Quantitative ICC confirmed that MMP-3 was highly expressed in LuM1 cells as compared to Colon26 and *MMP3*-KO cells (Fig. 7A). The MMP-3-high LuM1 cells (40.2 μm/h) rapidly migrated as compared to Colon26 cells (5.3 μm/h), and the knockout of MMP-3 (34.2 μm/h) significantly reduced the migration speed in




Fig. 7 MMP-3 is essential for cancer cell migration in confined spaces. **A** Bar graph (min to max) showing expression levels of MMP-3 in Colon26, LuM1, and MMP3-KO cells. Quantitative immunocytochemistry (qICC) was performed by measuring fluorescence intensity per cell. $n = 50$ cells, $p = 0.0296$ (Colon26 vs. LuM1), $p = 0.0108$ (LuM1 vs. MMP3-KO), unpaired t-test. ns, not significant. **(B, C)** Representative images **(B)** and migration speed **(C)** of cells in the scratch assay. Scale bars, 100 μm . $n = 3$ fields of view, $p < 0.0001$ (Colon26 vs. LuM1), $p = 0.0014$ (LuM1 vs. MMP3-KO), and $p < 0.0001$ (Colon26 vs. MMP3-KO), unpaired t-test. Data were expressed as means \pm S.E.M. Similar results were obtained in three independent experiments. **D** Representative photomicrographs of the Transwell migration assay. Upper images, eosin + methylene blue staining. Lower images, mitochondria staining. Scale bars, 500 μm . **E** Number of migrating cells in the Transwell migration assay. $n = 6$ wells, $p < 0.0026$ (Colon26 vs. LuM1), $p < 0.0001$ (LuM1 vs. MMP3-KO), and $p < 0.0001$ (Colon26 vs. MMP3-KO), unpaired t-test. Data were expressed as means \pm S.E.M. **F** Total area of migrating cells in the Transwell migration assay. $n = 6$ wells, $p < 0.0626$ (Colon26 vs. LuM1), $p = 0.0005$ (LuM1 vs. MMP3-KO), and $p < 0.0001$ (Colon26 vs. MMP3-KO), unpaired t-test. Data were expressed as means \pm S.E.M.

the 2D scratch assay (Fig. 7B, C). Importantly, MMP3-high LuM1 significantly migrated faster than the parental Colon26 and the LuM1/MMP3-KO cells in confined spaces in the Transwell migration assay (Fig. 7D–F). Knockout of MMP-3 significantly reduced the migration activity in the confined space (Fig. 7D–F).

These data indicate that high MMP-3 expression significantly promotes metastatic cancer cell migration in confined spaces.

MMP-3 digestion of Lamin A/C induces nuclear deformity required for increased migration in confined spaces in metastatic cancer

It has been shown that low Lamin A levels enhance confined cell migration and metastatic capacity in breast cancer [75]. The nucleus is the largest and stiffest cellular organelle, and nuclear deformation is required for migration [46, 47]. Consistently, the levels of nuclear atypia have been pathological indicators to diagnose the levels of malignancy [76]. Therefore, we hypothesized that MMP-3 digestion of Lamin A induces nuclear deformity and increased migration in metastatic cancer cells.

Notably, the MMP3-dependent Lamin A/C loss and MMP3-dependent nuclear deformity (nuclear atypia) were found in the rapidly migratory LuM1 cells (Fig. 8A, B; Figures S24, S25). MMP3-dependent loss of Lamin A/C lamina spheres was also observed in LuM1 cells in full-focused and 3D images (Figures S26, S27). In contrast, in Colon26 and MMP3-KO cells, Lamin A/C formed round-shaped nuclear laminas surrounding the chromatins and lining NE from inside (Fig. 7B; Figure S24). The rate of cells with MMP3-dependent lamina loss (83%) was significantly higher than that with preserved lamina (18%) in LuM1 cells (Fig. 7C; Figure S25). The rate of cells with MMP3-dependent nuclear deformity (58%) (loss of DNA area) was significantly higher than that with round-shaped nuclei (4%) in LuM1 cells (Fig. 7D; Figure S25). Consistently, MMP-3 expression level per cell tended to be negatively correlated with Lamin A/C expression level and Lamin A/C area in LuM1 cells (Fig. 7E, F). Moreover, LuM1 cells uniquely formed tumor-like cell aggregates with high MMP-3 expression, whereas the MMP-3-dependent lamina loss was observed in peripheral migrating cells (Figure S28). In some LuM1 cells, MMP-3 co-localized with Lamin A/C at the nuclear lamina, forming a round shape, indicating their direct binding and processing (Fig. 7G).

Nuclear deformity was significantly increased in MMP3-high LuM1 cells (63%) as compared to MMP3-low Colon26 (11%) and MMP3-KO cells (27%) (Fig. 7H), indicating that MMP-3 high expression caused nuclear deformity. Consistently, the rate of round nucleus was significantly reduced in MMP3-high LuM1 cells as compared to Colon26 (89%) and MMP3-KO cells (73%)

(Fig. 7I). Similarly, DNA areas per cell were significantly reduced in LuM1 cells as compared to Colon26 and MMP3-KO cells (Fig. 7J).

Lamin A/C expression was significantly higher in LuM1 than in Colon26, although not altered by MMP3-KO (Figure S29A). The Lamin A/C area was significantly more compact in LuM1 than in Colon26, although not altered by MMP3-KO (Figure S29B). Thus, Lamin A/C concentration in cells is associated with rapid migration and high MMPs expression, but not with MMP-3 alone.

These data indicate that MMP-3 digestion of Lamin A/C induces nuclear deformity required for increased cell migration in confined spaces in metastatic cancer.

High expression of MMP-3 and LMNA predicts poor prognosis in cancers

To investigate the clinical relevance of our findings, we analyzed the mRNA expression of *MMP3* and *LMNA* in a cohort of human cancer samples, using the HPA database. HNSC showed the highest *MMP3* expression, followed by colorectal cancer (CRC), among 17 cancer types (Fig. 9A). While *LMNA* expression was observed across various cancer types, HNSCs displayed significantly higher *LMNA* expression levels (Fig. 9B).

Furthermore, we assessed the prognostic significance of *MMP3* and *LMNA* expression in HNSC, rectum adenocarcinoma (AC), and pancreatic ductal adenocarcinoma (PDAC). High *MMP3* expression predicted shorter overall survival in patients suffering from stage III HNSC (Fig. 9C, Figure S30) (HR = 2.27, $p = 0.046$), stage I PDAC (Fig. 9D) (HR = 1278980479, $p = 0.023$), stage I rectum AC (Fig. 9E) (HR = 2983752184, $p = 0.02$), and stage I lung AC (Fig. 9F) (HR = 2.57, $p = 0.00067$). Moreover, High *LMNA* expression predicted shorter overall survival in patients suffering from stage I HNSC (Fig. 9G, Figure S31) (HR = 1236254195, $p = 0.088$), stage I PDAC (Fig. 9H) (HR = 5.46, $p = 0.015$), stage III rectum AC (Fig. 9I) (HR = 23.06, $p = 0.00011$), and stage I lung AC (Fig. 9J) (HR = 1.64, $p = 0.077$).

These data indicate that high expressions of *MMP3* and *LMNA* is a useful biomarker for predicting poor prognosis of patients with HNSC, PDAC, rectum and lung ACs at specific stages.

Nuclear MMP-3 and cleaved Lamin identify metastatic HNSC

To demonstrate the existence and clinical relevance of nuclear MMP-3 and cleaved Lamin, we next performed IHC of clinical tissue specimens of stage I (non-metastatic) and stage IV (metastatic) HNSC cases. The number of nuclear MMP3-positive cells in stage IV HNSC (32.1%) was significantly higher than in stage I HNSC (9.8%) (Fig. 10A, B; Table S1 and S2). Similarly, the number of cleaved Lamin-positive tumor cells in stage IV




Fig. 8 MMP3-dependent lamina loss and nuclear deformity (atypia) in rapidly migratory cancer cells. Immunocytochemistry (ICC) of MMP-3 (green) and Lamin A/C (red), and scratch assay were performed in Colon26, LuM1, and MMP3-KO cells. DNA was stained with DAPI (blue). Quantitative ICC was performed by measuring fluorescence intensity and cell area. **A** Representative confocal laser scanning microscopy (CLSM) images of MMP-3 and Lamin A/C in LuM1 cells. Arrows, MMP3-dependent Lamin A/C loss and MMP3-dependent nuclear deformity (atypia). Scale bar, 10 μm . DNA was stained with DAPI. **B** Representative haze reduction images of ICC. DAPI/DNA was shown in blue in merge 2 and cyan in merge 3. **C**, **D** Scatter bar plot showing the cellular rates with MMP3-dependent Lamin A/C loss (C) and nuclear deformity (D) in LuM1 cells. $n = 4$ fields of view (paired t-test), $p = 0.0015$ (C) and $p = 0.0038$ (D). Data were expressed as means \pm S.E.M. **E**, **F** Negative correlation between MMP-3 and Lamin A/C expression levels (E) or Lamin A/C area (F) per cell. $n = 20$ cells. **G** Representative CLSM images of MMP-3 and Lamin A/C co-localization at round-shaped nuclear lamina in LuM1 cells. Scale bar, 5 μm . **H** The rate of cells with nuclear deformity. $n = 4$ fields of view, $p < 0.0001$ (Colon26 vs. LuM1), $p = 0.0005$ (LuM1 vs. MMP3-KO), and $p = 0.0653$ (Colon26 vs. MMP3-KO), unpaired t-test. **I** Rate of cells with round nuclei. $n = 4$ fields of view, $p < 0.0001$ (Colon26 vs. LuM1), $p < 0.0001$ (LuM1 vs. MMP3-KO), and $p = 0.0097$ (Colon26 vs. MMP3-KO), unpaired t-test. **J** A box-and-whisker plot showing the DNA area per cell. $n = 70$, $p < 0.0001$ (Colon26 vs. LuM1), $p < 0.0058$ (LuM1 vs. MMP3-KO), unpaired t-test. Whiskers indicate 10–90 percentiles. Data were expressed as means \pm S.E.M




Fig. 9 High expression of *MMP3* and *LMNA* predicts a poor prognosis in cancers. **A, B** Pan-cancer analysis of *MMP3* (A) and *LMNA* (B) mRNA expression. **C-F** Kaplan-Meier plot of *MMP3*-high (red) and *MMP3*-low (black) patients with stage III HNSC (C), hazard ratio (HR) = 2.27, $p = 0.046$, $n = 35$ cases (low) and $n = 43$ cases (high); stage I pancreatic ductal adenocarcinoma (PDAC) (D), HR = 1,278,980,479, $p = 0.023$, $n = 6$ cases (low) and $n = 15$ cases (high); stage I rectum adenocarcinoma (AC) (E), HR = 2,983,752,184, $p = 0.02$, $n = 21$ cases (low) and $n = 9$ cases (high); stage I lung AC (F), HR = 2.57, $p = 0.00067$, $n = 95$ cases (low) and $n = 175$ cases (high). (G-J) Kaplan-Meier plot of *LMNA*-high (red) and *LMNA*-low (black) patients with stage I HNSC (G), HR = 12,362,541,955, $p = 0.088$, $n = 9$ cases (low) and $n = 16$ cases (high); stage I PDAC (H), HR = 5.46, $p = 0.015$, $n = 15$ cases (low) and $n = 6$ cases (high); stage III rectum AC (I), HR = 23.06, $p = 0.00011$, $n = 31$ cases (low) and $n = 20$ cases (high); stage I lung AC (J), HR = 1.64, $p = 0.077$, $n = 95$ cases (low) and $n = 175$ cases (high). Statistical significance was analyzed using the log-rank test

HNSC (44.5%) was significantly higher than in stage I (28.4%) (Fig. 10C). Notably, the co-occurrence of nuclear *MMP-3* and cleaved Lamin A within tumor cells was significantly more frequent in stage IV HNSC (27.8%) compared to stage I HNSC (6.9%) (Fig. 10D).

These findings collectively suggest that elevated levels of cleaved Lamin A, nuclear *MMP-3*, and their co-occurrence are associated with poor prognosis in patients suffering from HNSC, highlighting their potential as novel prognostic biomarkers (Fig. 11).

Discussion

Our data indicate that *MMP3* cleavage of nuclear Lamin A induces nuclear deformity (atypia), which is required for increased cell migration in confined spaces, and that this cleavage is autophagically co-secreted with EVs in metastatic cancer. Proteome, immunoEM, and ICC analyses revealed that *MMP-3* induced the autophagic

secretion of Lamin A/C with EVs in metastatic cancer. In nuclei, *MMP-3* was found to bind to Lamin A, transcriptional, and splicing factors. Structural analysis revealed the *MMP-3* cleavage site in Lamin A. It is supposed that *MMP-3* mature dimers digest Lamin A/C. Cleaved Lamin A localized in nuclear speckles and amphisomes with *MMP-3*, suggesting their autophagic co-transport and co-secretion with EVs. Clinically, high expressions of *MMP3* and *LMNA* predict poor prognosis of cancers such as HNSC, PDAC, rectum and lung ACs at specific stages. Indeed, nuclear *MMP-3* and cleaved Lamin were increased at the metastatic stage in HNSC as compared to the initial stage.

Our study indicates that *MMP-3* can bind to, promote the processing of, and co-transport Lamin A. A previous study reported that nuclear *MMP-2* directly cleaves Lamin A to generate a 50 kDa fragment but not Lamin B [77]. In contrast, the major Lamin A fragment in our




Fig. 10 Nuclear MMP-3 and cleaved Lamin identify metastatic HNSC. **A** Representative immunohistochemistry (IHC) images of MMP-3 (red) and cleaved Lamin (green) in non-metastatic (stage I) and metastatic (stage IV) HNSCs. Yellow regions, co-expression. Scale bars, 20 μ m. **B-D** Violin plots showing the rates of nuclear MMP3-positive cells (B), cleaved Lamin-positive cells (C), and nuclear MMP-3/cleaved Lamin double-positive cells (D). $n = 10$ cases (unpaired t-test), $p < 0.0001$ (B), $p = 0.0008$ (C), and $p < 0.0001$ (D)

study was 30 kDa. The difference suggests that cleavage sites in Lamin A were different between MMP-2 and MMP-3. MMP-mediated proteolysis of Lamin A reduces the nuclear matrix integrity, potentially altering cancer cell behavior. Our study suggested a causal relationship that MMP-3 digestion of Lamin A/C induced nuclear deformity required for increased migration in rapidly migratory LuM1 cells, whereas MMP3-low Colon26 and MMP3-KO cells showed lower migration speed [12, 14]. Consistently, low Lamin A levels enhanced confined cell migration and metastatic capacity in breast cancer [75]. Additionally, a few proteases have been shown to cleave Lamin A, including caspase-6 (aka. Mch2) [78, 79] and interleukin-1 β -converting enzyme (ICE)-related protease [80]. These studies have indicated that apoptosis was induced by protease-dependent cleavage of Lamin A. Additional studies reported that MMP-3 present in the cell nucleus is involved in apoptosis [81] and that overexpression of MMP-3 activated caspase-9, leading to apoptosis [21]. Nevertheless, our data show that both living (non-apoptotic) and dying (apoptotic or autophagic)

cells were seen upon MMP-3 overexpression with cleaved Lamin. Further studies are required to separate and distinguish autophagic EVs from apoptotic EVs. The differential cleavage of Lamin between living and dying cells may be due to the differences in MMP-3 expression. Moreover, nuclear MMP3-positive, cleaved Lamin-positive, and double-positive tumor cells were abundantly seen in human clinical HNSC tissue specimens. In addition, autophagic co-transport of Lamin A and MMP-3 was seen in living cells, suggesting that this co-transport to the extracellular space might be a key event in metastatic cancers. Thus, MMP-3 and Lamin A are secreted via the autophagic EV pathway in metastatic cancer cells.

Our data indicate that MMP3 digestion of Lamin A/C induced pro-migratory nuclear deformity (or nuclear atypia) in metastatic cancer cells. Consistently, it has been shown that the deformability of the nucleus is largely determined by expression of A-type lamins [82], although changes in B-type lamin expression can also impact nuclear elasticity [45]. Downregulation of lamin A/C could increase migration, as reduced lamin A/C




Fig. 11 Graphical abstract showing the roles of MMP-3 and Lamin A in cancers, and membrane traffic by nucleophagy, amphisomes, multivesicular bodies (MVBs), and extracellular vesicles (EVs). In addition, MMP-3-mediated cleavage of Lamin A/C induces nuclear deformity, which is required for metastatic cancer cell migration in confined spaces. ILV, intra-luminal vesicle. NE, nuclear envelope. PE, phosphatidylethanolamine

expression could result in a softer nucleus that could deform more easily and, therefore, migrate through tighter spaces than cells expressing higher lamin A/C levels [83, 84]. Indeed, cells with decreased lamin A/C levels migrate significantly faster through narrow constrictions in microfluidics devices and transwell plates with 3 μm pore sizes [85, 86]. Consistently, our data showed that MMP-3 knockout and nuclear lamina preservation

significantly reduced metastatic cancer cell migration in the Transwell migration assay. Moreover, cells at the periphery of a xenograft tumor model showed greater nuclear deformation and lower lamin A expression than cells in the tumor core, suggesting that subpopulations of cells with lower lamin A expression were more efficient at invasion *in vivo* [85]. Consistently, low Lamin A levels enhanced confined cell migration and metastatic

capacity in breast cancer [75]. On the other hand, Lamin A/C supports NE, which has a critical role in protecting the genome, and loss of NE integrity could damage DNA and potentially lead to cell death [45]. Consistently, we showed DNA fragmentation, a marker of dying cells, in MMP-3-high, cleaved Lamin-high cells. Additionally, Lamin A/C deregulation leads to various traits, including genomic instability and increased tolerance to mechanical insult, which can lead to more aggressive cancer and poorer prognosis [45, 84]. Overall, Lamin A/C expression may be a double-edged sword: low levels promote cell invasion by increasing nuclear deformability, while high levels protect against mechanical forces, such as increased interstitial pressure within the tumor, and some minimum function of Lamins is required for proper cell polarization and cytoskeletal organization [45]. Our data suggest that MMP3 digestion of Lamin A/C induced increased motility, the loss of NE integrity, and genome instability, which can lead to more aggressive cancer and poorer prognosis.

Our data also suggest that MMP-3 induced nucleophagy and subsequent autophagic EV secretion. MMP-3 cleavage of A-type Lamin destabilizes NE and can induce nucleophagy (or macronucleophagy). Our data showed that MMP-3 profoundly co-localized with LC3B and CD63 in nuclei, and cleaved Lamin co-localized with CD63 in nuclei. Relevantly, it was reported that sumoylated Lamin A/C was degraded by macronucleophagy [87]. Increasing evidence suggests that nucleophagy plays a critical role in preserving nuclear integrity by clearing dysfunctional nuclear materials, including nuclear proteins (Lamins, SIRT1, and histones), DNA-protein crosslinks, micronuclei, and chromatin fragments [48]. Fusion of nucleophagosomes with MVBs can generate nucleoamphisomes that are subsequently transported to the cytoplasm and fuse with the plasma membrane to secrete autophagic EVs. Thus, our data suggest that MMP-3 can induce nucleophagy and autophagic EV secretion accompanied by cleaved Lamin.

Our data also showed biophysical and biochemical evidence that MMP-3's invasion of the nucleus induces Lamin A/C loss and nuclear deformity and regulates various nuclear events, such as transcription, alternative splicing, and genome instability. Notably, proteolytic forms of MMP-3 generated Lamin A speckles in nuclei. Moreover, co-IP-LC-MS/MS revealed that MMP-3 could regulate transcription and alternative splicing. These data are consistent with a previous study showing that Lamin A/C speckles mediate the spatial organization of splicing factor compartments and RNA polymerase II transcription [88]. Another study has shown that Lamin A/C sustains polycomb group protein architecture, maintaining transcriptional repression at target genes [89]. Relevantly, our previous studies have shown that nuclear MMP-3

regulates transcriptional activation [14, 23, 24]. Regarding RNA regulation, our co-IP-proteomics revealed MMP-3 binding of RNA regulators such as hnRNA (A1, A2, A3, C, D, and H3 types), ELAVL1/HuR, and SRSF1 (serine and arginine-rich splicing factor 1). Consistently, it has been shown that MMP-3-dependent regulation of Rac1 pre-mRNA splicing is involved in hnRNP A1 [90]. Our interactome data also showed MMP-3 interaction with DNA topoisomerase 2 (Topo 2 A and 2B). It has been shown that MMP-3 and topoisomerases are involved in genome instability [10, 91]. Therefore, MMP-3 regulation of topoisomerase II can alter genome instability in cancer. Thus, it is suggested that nuclear MMP-3 is crucial in transcriptional regulation, alternative splicing, and genome instability.

Our data also suggest that extracellular Lamin A could be a novel biomarker of metastatic cancers. Our immunoEM data indicate that both EV-bound and vesicle-free Lamin A were secreted by metastatic cancer (Fig. 1J, Figure S4). The Minimal Information for Studies of Extracellular Vesicles (MISEV2018 and MISEV2023) states that Lamin A is a category IV EV marker found in large oncosomes and pathogenic/atypical states [29, 92]. However, no data confirmed EV-bound Lamin A in large oncosome papers [93]. The large oncosomes and apoptotic bodies were 1 to 10 μm in diameter and collectible from the pellet after the centrifugation at $10,000 \times g$ [93], while the large EVs defined in our present study were 0.5–1.0 μm in diameter. Thus, large oncosomes were much larger than our large EVs. Only one study reported that pathological levels of serum Lamin A are a potential biomarker that can predict adverse pregnancy outcomes [94]. The ExoCarta database have posted that LMNA was identified in sEVs derived from the following tissues/cell types: cancer cells (breast, colorectal, gastric, lymphoma, monocytic leukemia, ovarian, pancreatic, prostate and squamous carcinoma), mammary cancer-associated fibroblasts (CAF), stem cells (bone marrow mesenchymal stem cells, mesenchymal stem cells, and pluripotent stem cells), and normal cells (chondrocytes, embryonic kidney cells, foreskin fibroblasts, normal mammary epithelial cells, pancreatic ductal epithelial cells, and T lymphocytes) (http://exocarta.org/gene_summary?gene_id=4000). Most of these data appeared to be from mass spectrometry, but were not confirmed by western blotting and immunoEM. Moreover, the cleaved Lamin A has not been investigated in previous studies. In contrast, our study originally indicates that metalloprotease-cleaved Lamin A is co-secreted with EVs in metastatic cancer.

In addition to Lamin A, our study also suggests that another intermediate filament, Vimentin, could be processed by MMP-3 and secreted via the autophagy-amphisome-EV pathway. Many groups have reported extracellular serum Vimentin in cancers and other

pathological states. Consistent with our study, Vimentin (VIM) was the highly represented protein in pancreatic adenocarcinoma-derived extracellular vesicles and particles (EVPs) compared with adjacent paired normal tissue [95]. Also, serum Vimentin has been found in cancers such as glioblastoma [96], CRC [97], gastric cancer [98], and hepatocellular carcinoma [99]. Interestingly, serum Vimentin methylation has been found as a potential biomarker in CRC and gastric cancer [97, 98]. Serum Vimentin could also predict inflammatory diseases such as pediatric severe sepsis [100], atherosclerosis [101], autoimmunity [102], and non-alcoholic steatohepatitis [103]. Thus, serum Vimentin is found in both cancer and inflammatory diseases. Our data suggest that MMP-3 could process Vimentin, while other proteases, such as caspases [104, 105] and calpain [106], also process Vimentin. Intermediate filaments such as Vimentin and Lamin can be preferentially processed by proteases in diseases, due to the abundance of filamentous structures accessible to proteases and chaperones.

While the proteolytic processing of Lamin A/C by proteases is akin to post-translational modification (PTM) that dynamically induces nuclear deformity and nucleophagy, many PTMs are crucial for Lamin A/C metabolism and thus nuclear architecture and cell fate. Lamin A is initially translated as pre-lamin A, which undergoes a chain of PTMs at its C-terminal tail domain to become functionally useful. This process includes farnesylation by farnesyl transferase (FTase), cleavage of the terminal aaX motif by Zmpste24 or Rce1, carboxymethylation by ICMT, and a final cleavage by Zmpste24 to remove the modified cysteine [107]. Beyond maturation, Lamin A/C is regulated by various PTMs—such as phosphorylation, acetylation, SUMOylation, ubiquitylation, and palmitoylation—that influence its solubility, polymerization, localization, and interactions with chromatin and other proteins [108]. These modifications are essential for maintaining nuclear architecture and coordinating cellular processes throughout the cell cycle [108]. SUMOylation, which regulates the reassembly of Lamin A after the end of mitosis in the daughter cells, is regulated via the SUMO motif on lamin A [109]. Notably, nuclear accumulation of UBC9 contributes to SUMOylation of Lamin A/C and nucleophagy in response to DNA damage [87]. Phosphorylation, particularly at Ser22 and Ser392 by CDK1, facilitates Lamin A disassembly during mitosis and modulates enhancer activity, with aberrant phosphorylation implicated in disorders like progeria [110]. Another group has shown that CDK1 controls NE integrity via regulating the phosphorylation of Lamin A/C at Ser 22 and 392 sites [111]. A recent study showed that phosphorylation of Lamin A/C at Ser301 mediated CAF activation caused by androgen receptor loss [112]. Additionally, pronounced observation of micronuclei and NE

rupture have been observed in cancer cells. Kovacs et al. have shown that DNA damage induces NE rupture and micronuclei formation by phosphorylating Lamin A/C via ATR [113]. Similarly, another study showed that Doxorubicin, an anticancer drug, causes DNA damage and nuclear membrane injury by phosphorylating Lamin A/C, leading to cell death and cardiotoxicity [114, 115]. SUMOylation affects Lamin stability and chromatin binding, and mutations such as E203G/K reduce SUMOylation, contributing to diseases like familial cardiomyopathy and lipodystrophy [116, 117]. Acetylation, regulated by KAT8, supports nuclear integrity, while its loss leads to membrane defects and micronuclei formation [118]. Palmitoylation at specific cysteine residues, mediated by ZDHHC5 and reversed by ABHD7, is crucial for muscle cell differentiation and repair [119]. The impaired PTMs and cleavage of Lamin A may disrupt the proper localization, structure, and function, which can contribute to disease progression such as cancer, cardiomyopathy, or neurological disorders. Therefore, investigating the relationships among cleavage, PTMs, and secretion of Lamin A/C in cancers and laminopathies could provide valuable insights into their pathogenesis and therapeutic potential.

There are some limitations of the study. Firstly, we showed that MMP-3 and cleaved Lamin in EVs are crucial in aggressive cancers, such as metastatic HNSC and colorectal cancers. However, EV-Lamin A or EV-MMP3 have not been investigated in patient-derived liquid biopsy samples such as blood, saliva, or urine. Such investigations will be useful for establishing a new diagnostic and prognostic method to detect early-stage cancers and identify those with poor prognosis. Secondly, we showed dozens of MMP-3 cofactors, but IP-western blotting to confirm protein-protein interactions or in vitro cleavage assay using recombinant proteins has not been performed. MMP-3 interaction with or cleavage of nuclear proteins such as histones, Topoisomerase II, and hnRNPs will largely determine the genome and RNA status.

Conclusions

In conclusion, MMP-3 cleavage of nuclear Lamin A induces nuclear deformity, which is required for increased migration in confined spaces, nucleophagy, and the autophagic co-secretion with EVs in metastatic cancer. High expression of MMP3 and LMNA can predict poor prognosis in HNSC, PDAC, rectum and lung adenocarcinomas at specific stages.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12964-025-02549-6>.

Supplementary Material 1: Figure S1. Uncropped raw images of TEM of LuM1 tumoroid EVs and MMP3-KO EVs. Figure S2. Gene expression levels

of MMP3 and LMNA positively correlated in clinical tumor specimens of HNSC and pancreatic adenocarcinoma. Figure S3. Original WB images of MMP-3, cleaved Lamin, and CD63. Figure S4. ImmunoEM images of Lamin A/C, cleaved Lamin, and negative control in EV particle fractions of LuM1 cells cultured in serum-free RPMI medium. Figure S5. ImmunoEM images of EpCAM, Lamin A/C, and cleaved Lamin in the EV particle fraction of LuM1 cells cultured in Essential 8 / RPMI medium. Figure S6. Amino acid sequences of Lamin A fragments and dimers that were bound with MMP-3 were identified by LC-MS/MS. Figure S7. CBB staining showing a new band at 30 kDa appearing upon MMP-3 overexpression and cellular heat shock stress at 43°C for 5 min. Figure S8. Original WB images of FL and truncated MMP-3. Figure S9. Original WB images of FL and cleaved Lamins, Cat, Act, and GAPDH. Figure S10. Quantification of Lamin A speckles and nuclear size changes. Figure S11. Original CLSM images of Lamin A/C and MMP-3 in starved LuM1pGFP cells. Figure S12. Original CLSM images of Lamin A/C and MMP-3 in starved M3pGFP cells. Figure S13. An original ICC image of cleaved Lamin (red), MMP3-GFP (green), and nuclei (blue) stained with DAPI. Figure S14. Original CLSM images of cleaved Lamin and MMP-3 in starved LuM1pGFP cells. Figure S15. Original CLSM images of cleaved Lamin and MMP-3 in starved M3pGFP cells. Figure S16. Original CLSM images of CD63 and LC3B in unstarved LuM1 and starved LuM1pGFP cells. Figure S17. Original CLSM images of CD63 and LC3B in starved M3pGFP cells. Figure S18. Original CLSM images of LC3B and MMP-3 in unstarved LuM1 and starved LuM1pGFP cells. Figure S19. Original CLSM images of LC3B and MMP-3 in starved M3pGFP cells. Figure S20. Original CLSM images of CD63 and MMP-3 in unstarved LuM1 and starved LuM1pGFP cells. Figure S21. Original CLSM images of CD63 and MMP-3 in starved M3pGFP cells. Figure S22. Original CLSM images of cleaved Lamin and CD63 in unstarved LuM1 and starved LuM1pGFP cells. Figure S23. Original CLSM images of cleaved Lamin and LC3B in starved LuM1pGFP cells. Figure S24. Original CLSM images of MMP-3 and Lamin A/C in Colon26, LuM1, and MMP3-KO cells. Figure S25. Original CLSM images used for quantification of MMP3-dependent lamina loss and nuclear atypia. Figure S26. Representative full-focused ICC images of Lamin A/C and MMP-3 in Colon26, LuM1, and MMP3-KO cells. Figure S27. Representative 3D images of MMP-3 and Lamin A/C in Colon26, LuM1, and MMP3-KO cells. Figure S28. Representative auto full-focus ICC images of a tumor-like cell aggregate (tumoroid) of LuM1 cells. Figure S29. Floating bar graphs showing Lamin A/C expression level (A) and area (B) per cell, quantified from ICC images. Figure S30. Kaplan-Meier analysis of MMP3-high (red) and low (black) expression patients with HNSC, PDAC, rectum and lung ACs. Figure S31. Kaplan-Meier analysis of LMNA-high (red) and low (black) expression patients with HNSC, PDAC, rectum and lung ACs. Table S1. Rates of MMP-3 (+) nuclei and cleaved Lamin (+) nuclei in patient-derived tumor tissues of stage I HNSC. Table S2. Rates of MMP-3 (+) nuclei and cleaved Lamin (+) nuclei in patient-derived tumor tissues of stage IV HNSC

Acknowledgements

The authors thank Moemi Tsukano for immunoEM, Ross Tomaino for LC-MS/MS, Satoshi Iwasa for instruction in CLSM, and Nobuyuki Endo and Masao Nakazawa for instruction in the Keyence microscopy technique, and Yuka Okusha for generating CRISPR/Cas9-based MMP3-KO cells. BioRender was used to generate Figure 3 A and Figure 11.

Declaration of generative ai and ai-assisted technologies

During the preparation of this work, the author(s) used AlphaFold to predict the protein structures of MMP-3 and lamin A. After using this tool or service, the authors reviewed and edited the content as needed and take full responsibility for the publication's content.

Authors' contributions

Conceptualization, T.E.; methodology, T.E., C.S. and K.N.; formal analysis, T.E.; investigation, T.E. (cell culture, EV separation, and immunoEM for Figure 1; co-IP-LC-MS/MS for Figure 2; structural analysis and cleavage site prediction for Figs. 3 and 4; WB, cleavage assay, ICC, CLSM, qICC and migration assay for Figs. 4, 5, 6, 7 and 8), E.A.T. (3D cell culture, EV separation, TEM, particle distribution analysis, EV proteomics, heat map, and western blotting of EVs for Figure 1), K.N. (IHC of clinical specimens for Figure 10), and C.S. (3D cell culture, EV separation, EV proteomics, and western blotting of EVs for Figure 1); validation, T.E. (pan-cancer analysis and KM analysis for Figure 9), T.I. (cell culture and ICC), L.X. (KM analysis) and K.T. (structural analysis for

Figure 4); resources, T.E. (materials and microscopy), K.N. (clinical specimens), K.O. and S.K.C.; writing—original draft preparation and editing, T.E. and V.T.; visualization, T.E. (graphics) and K.T. (molecular structure for Figure 4 A); supervision, S.K.C.; project administration, T.E.; funding acquisition, T.E. and S.K.C. All authors read and agreed to the published version of the manuscript.

Funding

This research was funded by JSPS Kakenhi grants 23K28000 (to T.E.), 22KF0268 (to T.E. and M.S.), 25K02812 (to T.Y. and T.E.), 23K24768 (to H.O. and T.E.), 24K13239 (to K.O. and T.E.), 25K20246 (to K.T.), 24K13088 (to K.N.), and 23K11926 (to C.S.). S.K.C. was supported by NIH grants R01CA176326 and CA176326-05.

Data availability

Data is provided within the manuscript or supplementary information files.

Declarations

Ethics approval and consent to participate

The study was approved by the Okayama University Human Ethics Committee (Approval number: 1608–018), and informed consent was obtained from all patients.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

¹Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8525, Japan

²Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo 11566, Egypt

³Department of Oral Pathology and Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8525, Japan

⁴Council of Scientific & Industrial Research-Indian Institute of Toxicological Research, Lucknow 226001, India

⁵Research practicum program, Okayama University Dental School, Okayama 700-8525, Japan

⁶Department of Clinical Pharmacology, Harbin Medical University Cancer Hospital, Harbin 150040, China

⁷Department of Food and Health Sciences, Faculty of Environmental Studies, Hiroshima Institute of Technology, Hiroshima 731-5193, Japan

⁸Division of Molecular and Cellular Biology, Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA

Received: 19 July 2025 / Accepted: 14 November 2025

Published online: 15 January 2026

References

- Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2024;74:229–63.
- Mody MD, Rocco JW, Yom SS, Haddad RI, Saba NF. Head and neck cancer. *Lancet.* 2021;398:2289–99.
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021;71:209–49.
- Johnson DE, Burtress B, Leemans CR, Lui WY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. *Nat Rev Dis Primers.* 2020;6:92.
- Okano S, Homma A, Kiyota N, Tahara M, Hanai N, Asakage T, Matsuura K, Ogawa T, Saito Y, Sano D, et al. Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck. *Jpn J Clin Oncol.* 2021;51:173–9.

6. Hey S, Linder S. Matrix metalloproteinases at a glance. *J Cell Sci* 2024, 137.
7. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. *Cell*. 2010;141:52–67.
8. Horejs CM. Basement membrane fragments in the context of the epithelial-to-mesenchymal transition. *Eur J Cell Biol*. 2016;95:427–40.
9. Giannelli G, Antonaci S. Biological and clinical relevance of Laminin-5 in cancer. *Clin Exp Metastasis*. 2000;18:439–43.
10. Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, Leake D, Godden EL, Albertson DG, Nieto MA, et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. *Nature*. 2005;436:123–7.
11. Taha EA, Sogawa C, Okusha Y, Kawai H, Oo MW, Elseoudi A, et al. Knockout of MMP3 weakens solid tumor organoids and cancer extracellular vesicles. *Cancers (Basel)*. 2020. <https://doi.org/10.3390/cancers12051260>.
12. Okusha Y, Eguchi T, Sogawa C, Okui T, Nakano K, Okamoto K, Kozaki KI. The intranuclear PEX domain of MMP involves proliferation, migration, and metastasis of aggressive adenocarcinoma cells. *J Cell Biochem*. 2018;119:7363–76.
13. Shimoda M, Khokha R. Metalloproteinases in extracellular vesicles. *Biochim Biophys Acta Mol Cell Res*. 2017;1864:1989–2000.
14. Okusha Y, Eguchi T, Tran MT, Sogawa C, Yoshida K, Itagaki M, et al. Extracellular vesicles enriched with moonlighting metalloproteinase are highly transmissible, pro-tumorigenic, and trans-activates cellular communication network factor (CCN2/CTGF): CRISPR against cancer. *Cancers (Basel)*. 2020. <https://doi.org/10.3390/cancers12040881>.
15. Belotti D, Paganoni P, Giavazzi R. MMP inhibitors: experimental and clinical studies. *Int J Biol Markers*. 1999;14:232–8.
16. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. *Cancer Res*. 1994;54:4726–8.
17. Bassiouni W, Ali MAM, Schulz R. Multifunctional intracellular matrix metalloproteinases: implications in disease. *FEBS J*. 2021;288:7162–82.
18. Jobin PG, Butler GS, Overall CM. New intracellular activities of matrix metalloproteinases shine in the moonlight. *Biochim Biophys Acta Mol Cell Res*. 2017;1864:2043–55.
19. Cauwe B, Opendenacker G. Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. *Crit Rev Biochem Mol Biol*. 2010;45:351–423.
20. Kandasamy AD, Schulz R. Glycogen synthase kinase-3beta is activated by matrix metalloproteinase-2 mediated proteolysis in cardiomyoblasts. *Cardiovasc Res*. 2009;83:698–706.
21. Kim EM, Shin EJ, Lee JA, Son HJ, Choi DH, Han JM, Hwang O. Caspase-9 activation and Apaf-1 cleavage by MMP-3. *Biochem Biophys Res Commun*. 2014;453:563–8.
22. Mannello F, Medda V. Nuclear localization of matrix metalloproteinases. *Prog Histochem Cytochem*. 2012;47:27–58.
23. Eguchi T, Kubota S, Kawata K, Mukudai Y, Uehara J, Ohgawara T, Ibaragi S, Sasaki A, Kuboki T, Takigawa M. Novel transcription-factor-like function of human matrix metalloproteinase 3 regulating the CTGF/CCN2 gene. *Mol Cell Biol*. 2008;28:2391–413.
24. Eguchi T, Calderwood SK, Takigawa M, Kubota S, Kozaki KI. Intracellular MMP3 promotes HSP gene expression in collaboration with chromobox proteins. *J Cell Biochem*. 2017;118:43–51.
25. Shimizu-Hirota R, Xiong W, Baxter BT, Kunkel SL, Maillard I, Chen XW, Sabeh F, Liu R, Li XY, Weiss SJ. MT1-MMP regulates the PI3Kdelta.Mi-2/NuRD-dependent control of macrophage immune function. *Genes Dev*. 2012;26:395–413.
26. Marchant DJ, Bellac CL, Moraes TJ, Wadsworth SJ, Dufour A, Butler GS, Bilawchuk LM, Hendry RG, Robertson AG, Cheung CT, et al. A new transcriptional role for matrix metalloproteinase-12 in antiviral immunity. *Nat Med*. 2014;20:493–502.
27. Kim K, Punj V, Kim JM, Lee S, Ulmer TS, Lu W, Rice JC, An W. MMP-9 facilitates selective proteolysis of the histone H3 tail at genes necessary for proficient osteoclastogenesis. *Genes Dev*. 2016;30:208–19.
28. Ali MAM, Garcia-Vilas JA, Cromwell CR, Hubbard BP, Hendzel MJ, Schulz R. Matrix metalloproteinase-2 mediates ribosomal RNA transcription by cleaving nucleolar histones. *FEBS J*. 2021;288:6736–51.
29. Welsh JA, Goberdhan DCI, O'Driscoll L, Buzas EI, Blenkiron C, Bussolati B, Cai H, Di Vizio D, Driedonks TAP, Erdbrugger U, et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. *J Extracell Vesicles*. 2024;13:e12404.
30. Sheta M, Taha EA, Lu Y, Eguchi T. Extracellular vesicles: new classification and tumor immunosuppression. *Biology*. 2023. <https://doi.org/10.3390/biology12010110>.
31. Ono K, Eguchi T, Sogawa C, Calderwood SK, Futagawa J, Kasai T, Seno M, Okamoto K, Sasaki A, Kozaki KI. HSP-enriched properties of extracellular vesicles involve survival of metastatic oral cancer cells. *J Cell Biochem*. 2018;119:7350–62.
32. Taha EA, Ono K, Eguchi T. Roles of extracellular HSPs as biomarkers in immune surveillance and immune evasion. *Int J Mol Sci*. 2019. <https://doi.org/10.3390/ijms20184588>.
33. Umemori K, Ono K, Eguchi T, Kawai H, Nakamura T, Ogawa T, Yoshida K, Kanemoto H, Sato K, Obata K, et al. EpEX, the soluble extracellular domain of EpCAM, resists cetuximab treatment of EGFR-high head and neck squamous cell carcinoma. *Oral Oncol*. 2023;142:106433.
34. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and MicroRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol*. 2007;9:654–9.
35. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. *J Cell Biol*. 2013;200:373–83.
36. Peinado H, Zhang H, Matei IR, Costa-Silva B, Hoshino A, Rodrigues G, Psaila B, Kaplan RN, Bromberg JF, Kang Y, et al. Pre-metastatic niches: organ-specific homes for metastases. *Nat Rev Cancer*. 2017;17:302–17.
37. Eguchi T, Sheta M, Fujii M, Calderwood SK. Cancer extracellular vesicles, tumoroid models, and tumor microenvironment. *Semin Cancer Biol*. 2022;86:112–26.
38. Ono K, Sogawa C, Kawai H, Tran MT, Taha EA, Lu Y, Oo MW, Okusha Y, Okamura H, Ibaragi S, et al. Triple knockdown of CDC37, HSP90-alpha and HSP90-beta diminishes extracellular vesicles-driven malignancy events and macrophage M2 polarization in oral cancer. *J Extracell Vesicles*. 2020;9:1769373.
39. Fujiwara T, Eguchi T, Sogawa C, Ono K, Murakami J, Ibaragi S, Asaumi JI, Calderwood SK, Okamoto K, Kozaki KI. Carcinogenic epithelial-mesenchymal transition initiated by oral cancer exosomes is inhibited by anti-EGFR antibody cetuximab. *Oral Oncol*. 2018;86:251–7.
40. Jeppesen DK, Fenix AM, Franklin JL, Higginbotham JN, Zhang Q, Zimmerman LJ, Liebler DC, Ping J, Liu Q, Evans R, et al. Reassessment of exosome composition. *Cell*. 2019;177:428–e445418.
41. Lauritzen I, Bini A, Becot A, Gay AS, Badot C, Pagnotta S, Chami M, Checler F. Presenilins as hub proteins controlling the endocytic and autophagic pathways and small extracellular vesicle secretion. *J Extracell Vesicles*. 2025;14:e70019.
42. Chen YD, Fang YT, Cheng YL, Lin CF, Hsu LJ, Wang SY, Anderson R, Chang CP, Lin YS. Exophagy of Annexin A2 via RAB11, RAB8A and RAB27A in IFN-gamma-stimulated lung epithelial cells. *Sci Rep*. 2017;7:5676.
43. Eguchi T, Sogawa C, Okusha Y, Uchibe K, Inuma R, Ono K, et al. Organoids with cancer stem cell-like properties secrete exosomes and HSP90 in a 3D nanoenvironment. *PLoS One*. 2018;13:e0191109.
44. Sobo JM, Alagna NS, Sun SX, Wilson KL, Reddy KL. Lamins: the backbone of the nucleocytoskeleton interface. *Curr Opin Cell Biol*. 2024;86:102313.
45. Bell ES, Lammerding J. Causes and consequences of nuclear envelope alterations in tumour progression. *Eur J Cell Biol*. 2016;95:449–64.
46. McGregor AL, Hsia CR, Lammerding J. Squish and squeeze-the nucleus as a physical barrier during migration in confined environments. *Curr Opin Cell Biol*. 2016;40:32–40.
47. Wolf K, Te Lindert M, Krause M, Alexander S, Te Riet J, Willis AL, Hoffman RM, Figdor CG, Weiss SJ, Friedl P. Physical limits of cell migration: control by ECM space and nuclear deformation and tuning by proteolysis and traction force. *J Cell Biol*. 2013;201:1069–84.
48. Ji F, Dai E, Kang R, Klionsky DJ, Liu T, Hu Y, Tang D, Zhu K. Mammalian nucleophagy: process and function. *Autophagy*. 2025;21:1396–412.
49. Lai CP, Kim EY, Badr CE, Weissleder R, Mempel TR, Tannous BA, Breakefield XO. Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. *Nat Commun*. 2015;6:7029.
50. Namba Y, Sogawa C, Okusha Y, Kawai H, Itagaki M, Ono K, Murakami J, Aoyama E, Ohyama K, Asaumi JI, et al. Depletion of lipid efflux pump ABCG1 triggers the intracellular accumulation of extracellular vesicles and reduces aggregation and tumorigenesis of metastatic cancer cells. *Front Oncol*. 2018;8:376.
51. Sogawa C, Eguchi T, Tran MT, Ishige M, Trin K, Okusha Y, et al. Antiparkinson drug bntropine suppresses tumor growth, circulating tumor cells, and metastasis by acting on SLC6A3/DAT and reducing STAT3. *Cancers (Basel)*. 2020. <https://doi.org/10.3390/cancers12020523>.

52. Eguchi T, Cszimadia E, Kawai H, Sheta M, Yoshida K, Prince TL, et al. SCAND1 reverses epithelial-to-mesenchymal transition (EMT) and suppresses prostate cancer growth and migration. *Cells*. 2022. <https://doi.org/10.3390/cells11243993>.
53. Eguchi T, Okusha Y, Lu Y, Ono K, Taha EA, Fukuoka S. Comprehensive method for exosome isolation and proteome analysis for detection of CCN factors in/on exosomes. *Methods Mol Biol*. 2023;2582:59–76.
54. Eguchi T, Sogawa C, Ono K, Matsumoto M, Tran MT, Okusha Y, et al. Cell stress induced stressome release including damaged membrane vesicles and extracellular HSP90 by prostate cancer cells. *Cells*. 2020. <https://doi.org/10.3390/cells9030755>.
55. Szklarczyk D, Nastou K, Koutrouli M, Kirsch R, Mehryary F, Hachilif R, Hu D, Peluso ME, Huang Q, Fang T, et al. The STRING database in 2025: protein networks with directionality of regulation. *Nucleic Acids Res*. 2025;53:D730–7.
56. Turk BE, Huang LL, Piro ET, Cantley LC. Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. *Nat Biotechnol*. 2001;19:661–7.
57. Ono K, Okusha Y, Tran MT, Umemori K, Eguchi T. Western blot protocols for analysis of CCN proteins and fragments in exosomes, vesicle-free fractions, and cells. *Methods Mol Biol*. 2023;2582:39–57.
58. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson A, Kampf C, Sjostedt E, Asplund A, et al. Proteomics. Tissue-based map of the human proteome. *Science*. 2015;347:1260419.
59. Ono K, Eguchi T. Large-scale databases and portals on cancer genome to analyze chaperone genes correlated to patient prognosis. *Methods Mol Biol*. 2023;2693:293–306.
60. Györfy B. Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. *Innov (Camb)*. 2024;5:100625.
61. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov*. 2012;2:401–4.
62. Burke B, Stewart CL. The nuclear lamins: flexibility in function. *Nat Rev Mol Cell Biol*. 2013;14:13–24.
63. Andres V, Gonzalez JM. Role of A-type lamins in signaling, transcription, and chromatin organization. *J Cell Biol*. 2009;187:945–57.
64. Dechat T, Pflieger K, Sengupta K, Shimi T, Shumaker DK, Solimando L, Goldman RD. Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin. *Genes Dev*. 2008;22:832–53.
65. Okamoto T, Akaike T, Sawa T, Miyamoto Y, van der Vliet A, Maeda H. Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. *J Biol Chem*. 2001;276:29596–602.
66. Schopf FH, Biebl MM, Buchner J. The HSP90 chaperone machinery. *Nat Rev Mol Cell Biol*. 2017;18:345–60.
67. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis. *Trends Biochem Sci*. 2006;31:164–72.
68. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. *Nat Rev Cancer*. 2005;5:761–72.
69. Koo BH, Kim YH, Han JH, Kim DS. Dimerization of matrix metalloproteinase-2 (MMP-2): functional implication in MMP-2 activation. *J Biol Chem*. 2012;287:22643–53.
70. Ingvarsen S, Madsen DH, Hillig T, Lund LR, Holmbeck K, Behrendt N, Engelholm LH. Dimerization of endogenous MT1-MMP is a regulatory step in the activation of the 72-kDa gelatinase MMP-2 on fibroblasts and fibrosarcoma cells. *Biol Chem*. 2008;389:943–53.
71. Wang D, Yu L. Migrasome biogenesis: when biochemistry meets biophysics on membranes. *Trends Biochem Sci*. 2024;49:829–40.
72. Huang Y, Zucker B, Zhang S, Elias S, Zhu Y, Chen H, Ding T, Li Y, Sun Y, Lou J, et al. Migrasome formation is mediated by assembly of micron-scale tetraspanin macromolecules. *Nat Cell Biol*. 2019;21:991–1002.
73. Lou E, Verollet C, Winkler F, Zurzolo C, Valdebenito-Silva S, Eugenin E. Tunneling nanotubes and tumor microtubes-emerging data on their roles in intercellular communication and pathophysiology: summary of an International FASEB catalyst conference October 2023. *FASEB J*. 2024;38:e23514.
74. Zurzolo C. Tunneling nanotubes: reshaping connectivity. *Curr Opin Cell Biol*. 2021;71:139–47.
75. Bell ES, Shah P, Zuela-Sopliniak N, Kim D, Varlet AA, Morival JLP, McGregor AL, Isermann P, Davidson PM, Elacqua JJ, et al. Low lamin A levels enhance confined cell migration and metastatic capacity in breast cancer. *Oncogene*. 2022;41:4211–30.
76. Katayama A, Toss MS, Parkin M, Ellis IO, Quinn C, Rakha EA. Atypia in breast pathology: what pathologists need to know. *Pathology*. 2022;54:20–31.
77. Baghirova S, Hughes BG, Poirier M, Kondo MY, Schulz R. Nuclear matrix metalloproteinase-2 in the cardiomyocyte and the ischemic-reperfused heart. *J Mol Cell Cardiol*. 2016;94:153–61.
78. Lee SC, Chan J, Clement MV, Pervaiz S. Functional proteomics of resveratrol-induced colon cancer cell apoptosis: caspase-6-mediated cleavage of lamin A is a major signaling loop. *Proteomics*. 2006;6:2386–94.
79. Takahashi A, Alnemri ES, Lazebnik YA, Fernandes-Alnemri T, Litwack G, Moir RD, Goldman RD, Poirier GG, Kaufmann SH, Earnshaw WC. Cleavage of lamin A by Mch2 alpha but not CPP32: multiple Interleukin 1 beta-converting enzyme-related proteases with distinct substrate recognition properties are active in apoptosis. *Proc Natl Acad Sci U S A*. 1996;93:8395–400.
80. Takahashi A, Musy PY, Martins LM, Poirier GG, Moyer RW, Earnshaw WC. CrmA/SPI-2 inhibition of an endogenous ICE-related protease responsible for lamin A cleavage and apoptotic nuclear fragmentation. *J Biol Chem*. 1996;271:32487–90.
81. Si-Tayeb K, Monvoisin A, Mazzocco C, Lepreux S, Decossas M, Cubel G, Taras D, Blanc JF, Robinson DR, Rosenbaum J. Matrix metalloproteinase 3 is present in the cell nucleus and is involved in apoptosis. *Am J Pathol*. 2006;169:1390–401.
82. Lammerding J, Fong LG, Ji JY, Reue K, Stewart CL, Young SG, Lee RT. Lamins A and C but not lamin B1 regulate nuclear mechanics. *J Biol Chem*. 2006;281:25768–80.
83. Ferrari R, Infante E, Chavrier P. Nucleus-Invadopodia duo during cancer invasion. *Trends Cell Biol*. 2019;29:93–6.
84. Dubik N, Mai S. Lamin A/C: function in normal and tumor cells. *Cancers (Basel)* 2020, 12.
85. Harada T, Swift J, Irianto J, Shin JW, Spinler KR, Athirasala A, Diegmiller R, Dingal PC, Ivanovska IL, Discher DE. Nuclear lamin stiffness is a barrier to 3D migration, but softness can limit survival. *J Cell Biol*. 2014;204:669–82.
86. Shin JW, Spinler KR, Swift J, Chasis JA, Mohandas N, Discher DE. Lamins regulate cell trafficking and lineage maturation of adult human hematopoietic cells. *Proc Natl Acad Sci USA*. 2013;110:18892–7.
87. Li Y, Jiang X, Zhang Y, Gao Z, Liu Y, Hu J, Hu X, Li L, Shi J, Gao N. Nuclear accumulation of UBC9 contributes to sumoylation of lamin A/C and nucleophagy in response to DNA damage. *J Exp Clin Cancer Res*. 2019;38:67.
88. Kumaran RI, Muralikrishna B, Parnaik VK. Lamin A/C speckles mediate spatial organization of splicing factor compartments and RNA polymerase II transcription. *J Cell Biol*. 2002;159:783–93.
89. Cesarini E, Mozzetta C, Marullo F, Gregoret F, Gargiulo A, Columbaro M, Cortesi A, Antonelli L, Di Pelino S, Squarzone S, et al. Lamin A/C sustains PcG protein architecture, maintaining transcriptional repression at target genes. *J Cell Biol*. 2015;211:533–51.
90. Pelisch F, Khauv D, Riso G, Stallings-Mann M, Blaustein M, Quadrana L, Radisky DC, Srebrow A. Involvement of HnRNP A1 in the matrix metalloproteinase-3-dependent regulation of Rac1 pre-mRNA splicing. *J Cell Biochem*. 2012;113:2319–29.
91. Pommier Y, Nussenzweig A, Takeda S, Austin C. Human topoisomerases and their roles in genome stability and organization. *Nat Rev Mol Cell Biol*. 2022;23:407–27.
92. Thery C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Antoniou A, Arab T, Archer F, Atkin-Smith GK, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the international society for extracellular vesicles and update of the MISEV2014 guidelines. *J Extracell Vesicles*. 2018;7:1535750.
93. Minciacchi VR, Spinelli C, Reis-Sobreiro M, Cavallini L, You S, Zandian M, Li X, Mishra R, Chiarugi P, Adam RM, et al. MYC mediates large Oncosome-Induced fibroblast reprogramming in prostate cancer. *Cancer Res*. 2017;77:2306–17.
94. Chen L, Xiu Y, Wu Q, Wang Y, Zhang Y, Xue J, Wang Q, Yuan Z. Maternal serum lamin A is a potential biomarker that can predict adverse pregnancy outcomes. *Ebiomedicine*. 2022;77:103932.
95. Hoshino A, Kim HS, Bojmar L, Gyan KE, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S, et al. Extracellular vesicle and particle biomarkers define multiple human cancers. *Cell*. 2020;182:1044–e10611018.
96. Saito T, Muragaki Y, Komori A, Nitta M, Tsuzuki S, Koriyama S, Ro B, Kawamata T. Increase in serum vimentin levels in patients with glioma and its correlation with prognosis of patients with glioblastoma. *Neurosurg Rev*. 2023;46:202.
97. Shirahata A, Hibi K. Serum vimentin methylation as a potential marker for colorectal cancer. *Anticancer Res*. 2014;34:4121–5.

98. Shirahata A, Sakuraba K, Kitamura Y, Yokomizo K, Gotou T, Saitou M, Kigawa G, Nemoto H, Sanada Y, Hibi K. Detection of vimentin methylation in the serum of patients with gastric cancer. *Anticancer Res.* 2012;32:791–4.
99. Sun S, Poon RT, Lee NP, Yeung C, Chan KL, Ng IO, et al. Proteomics of hepatocellular carcinoma: serum vimentin as a surrogate marker for small tumors ($\leq 2\text{ cm}$). *J Proteome Res.* 2010;9:1923–30.
100. Miao H, Cui Y, Lu Y, Sun T, Dou J, Ren Y, et al. Serum vimentin predicts mortality in pediatric severe sepsis: a prospective observational study. *Int J Infect Dis.* 2022;121:141–7.
101. Liang Y, Li L, Chen Y, Zhang S, Li Z, Xiao J, Wei D. Research progress on the role of intermediate filament vimentin in atherosclerosis. *DNA Cell Biol.* 2021;40:1495–502.
102. Musaeelyan A, Lapin S, Nazarov V, Tkachenko O, Gilburd B, Mazing A, et al. Vimentin as antigenic target in autoimmunity: a comprehensive review. *Autoimmun Rev.* 2018;17:926–34.
103. Lee SJ, Yoo JD, Choi SY, Kwon OS. The expression and secretion of vimentin in the progression of non-alcoholic steatohepatitis. *BMB Rep.* 2014;47:457–62.
104. Byun Y, Chen F, Chang R, Trivedi M, Green KJ, Cryns VL. Caspase cleavage of vimentin disrupts intermediate filaments and promotes apoptosis. *Cell Death Differ.* 2001;8:443–50.
105. Morishima N. Changes in nuclear morphology during apoptosis correlate with vimentin cleavage by different caspases located either upstream or downstream of Bcl-2 action. *Genes Cells.* 1999;4:401–14.
106. Phillips CL, Fu D, Herring LE, Armao D, Snider NT. Calpain-mediated proteolysis of vimentin filaments is augmented in giant axonal neuropathy fibroblasts exposed to hypotonic stress. *Front Cell Dev Biol.* 2022;10:1008542.
107. Tiwari V, Alam MJ, Bhatia M, Navya M, Banerjee SK. The structure and function of lamin A/C: special focus on cardiomyopathy and therapeutic interventions. *Life Sci.* 2024;341:122489.
108. Vivante A, Shoval I, Garini Y. The dynamics of lamin a during the cell cycle. *Front Mol Biosci.* 2021;8:705595.
109. Moriuchi T, Kuroda M, Kusumoto F, Osumi T, Hirose F. Lamin A reassembly at the end of mitosis is regulated by its SUMO-interacting motif. *Exp Cell Res.* 2016;342:83–94.
110. Ikegami K, Secchia S, Almakki O, Lieb JD, Moskowitz IP. Phosphorylated lamin A/C in the nuclear interior binds active enhancers associated with abnormal transcription in Progeria. *Dev Cell.* 2020;52:699–e713611.
111. Liu S, Xiong F, Dou Z, Chu L, Yao Y, Wang M, Yao X, Liu X, Wang Z. Phosphorylation of lamin A/C regulates the structural integrity of the nuclear envelope. *J Biol Chem.* 2025;301:108033.
112. Ghosh S, Isma J, Ostano P, Mazzeo L, Toniolo A, Das M, White JR, Simon C, Paolo Dotto G. Nuclear lamin A/C phosphorylation by loss of androgen receptor leads to cancer-associated fibroblast activation. *Nat Commun.* 2024;15:7984.
113. Kovacs MT, Vallette M, Wiertsema P, Dingli F, Loew D, Nader GPF, Piel M, Ceccaldi R. DNA damage induces nuclear envelope rupture through ATR-mediated phosphorylation of lamin A/C. *Mol Cell.* 2023;83:3659–e36683610.
114. Tiwari V, Salgar S, Jorvekar SB, Kumbhar BM, Arava SK, Borkar RM, Banerjee SK. Doxorubicin-induced phosphorylation of lamin A/C enhances DNMT1 and activates cardiomyocyte death via suppressing GATA-4 and Bcl-xL in rat heart. *Biochim Biophys Acta Mol Basis Dis.* 2025;1871:167692.
115. Tiwari V, Gupta P, Malladi N, Salgar S, Banerjee SK. Doxorubicin induces phosphorylation of lamin A/C and loss of nuclear membrane integrity: a novel mechanism of cardiotoxicity. *Free Radic Biol Med.* 2024;218:94–104.
116. Simon DN, Domaradzki T, Hofmann WA, Wilson KL. Lamin A tail modification by SUMO1 is disrupted by Familial partial lipodystrophy-causing mutations. *Mol Biol Cell.* 2013;24:342–50.
117. Zhang YQ, Sarge KD. Sumoylation regulates lamin A function and is lost in lamin A mutants associated with Familial cardiomyopathies. *J Cell Biol.* 2008;182:35–9.
118. Karoutas A, Szymanski W, Rausch T, Guhathakurta S, Rog-Zielinska EA, Peyronnet R, Seyfferth J, Chen HR, de Leeuw R, Herquel B, et al. The NSL complex maintains nuclear architecture stability via lamin A/C acetylation. *Nat Cell Biol.* 2019;21:1248–60.
119. Shen Y, Zheng LL, Fang CY, Xu YY, Wang C, Li JT, Lei MZ, Yin M, Lu HJ, Lei QY, Qu J. ABHD7-mediated depalmitoylation of lamin A promotes myoblast differentiation. *Cell Rep.* 2024;43:113720.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.